{ "version": "2.2", "instance": { "iva-20260630xex99d1.htm": { "nsprefix": "iva", "nsuri": "http://www.inventivapharma.com/20260630", "dts": { "schema": { "local": [ "iva-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/rol_ifrs_ea-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2025-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/full_ifrs-cor_2025-03-27.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/currency/2025/currency-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd" ] }, "calculationLink": { "local": [ "iva-20260630_cal.xml" ] }, "definitionLink": { "local": [ "iva-20260630_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions-ea/dim_ifrs_ea_2025-03-27_role-995000.xml", "https://xbrl.ifrs.org/taxonomy/2025-03-27/full_ifrs/dimensions/dim_full_ifrs_2025-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "iva-20260630_lab.xml" ] }, "presentationLink": { "local": [ "iva-20260630_pre.xml" ] }, "inline": { "local": [ "iva-20260630xex99d1.htm" ] } }, "keyStandard": 226, "keyCustom": 203, "axisStandard": 28, "axisCustom": 4, "memberStandard": 32, "memberCustom": 126, "hidden": { "total": 9, "http://xbrl.sec.gov/dei/2025": 8, "http://www.inventivapharma.com/20260630": 1 }, "contextCount": 541, "entityCount": 1, "segmentCount": 172, "elementCount": 718, "unitCount": 19, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full": 1107, "http://xbrl.sec.gov/dei/2025": 8 }, "report": { "R1": { "role": "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": null, "uniqueAnchor": null }, "R2": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "00100 - Statement - Interim condensed consolidated statement of financial position", "shortName": "Interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:DeferredTaxAssets", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R3": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "00200 - Statement - Interim condensed consolidated statement of income (loss)", "shortName": "Interim condensed consolidated statement of income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R4": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLossParenthetical", "longName": "00205 - Statement - Interim condensed consolidated statement of income (loss) (Parenthetical)", "shortName": "Interim condensed consolidated statement of income (loss) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DilutionGainLossOfAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R5": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "longName": "00300 - Statement - Interim condensed consolidated statement of comprehensive income (loss)", "shortName": "Interim condensed consolidated statement of comprehensive income (loss)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R6": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "longName": "00400 - Statement - Interim condensed consolidated statement of changes in shareholders' equity", "shortName": "Interim condensed consolidated statement of changes in shareholders' equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_gIxtGFAcCUyb_DHWkZ1Www", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2025_To_6_30_2025_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember_JT_4mjxbxE240j-zM_x3mw", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R7": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical", "longName": "00405 - Statement - Interim condensed consolidated statement of changes in shareholders' equity (Parenthetical)", "shortName": "Interim condensed consolidated statement of changes in shareholders' equity (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:IssueOfEquity", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows", "longName": "00500 - Statement - Interim condensed consolidated statement of cash flows", "shortName": "Interim condensed consolidated statement of cash flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:AdjustmentsForDepreciationAmortisationAndProvisions", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R9": { "role": "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlowsParenthetical", "longName": "00505 - Statement - Interim condensed consolidated statement of cash flows (Parenthetical)", "shortName": "Interim condensed consolidated statement of cash flows (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:AdjustmentsForGainLossOnLeaseModification", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:AdjustmentsForGainLossOnLeaseModification", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformation", "longName": "10101 - Disclosure - Company information", "shortName": "Company information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:CompanyInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance", "longName": "10201 - Disclosure - Basis of preparation and statement of compliance", "shortName": "Basis of preparation and statement of compliance", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:BasisOfPreparationAndStatementOfComplianceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:BasisOfPreparationAndStatementOfComplianceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples", "longName": "10301 - Disclosure - Accounting principles", "shortName": "Accounting principles", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition", "longName": "10401 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss", "longName": "10501 - Disclosure - Notes to the interim condensed consolidated statement of income (loss)", "shortName": "Notes to the interim condensed consolidated statement of income (loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation", "longName": "10601 - Disclosure - Other financial information", "shortName": "Other financial information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DisclosureOfOtherFinancialInformationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies", "longName": "20302 - Disclosure - Accounting principles (Policies)", "shortName": "Accounting principles (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfMaterialAccountingPolicyInformationExplanatory", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables", "longName": "30203 - Disclosure - Basis of preparation and statement of compliance (Tables)", "shortName": "Basis of preparation and statement of compliance (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables", "longName": "30303 - Disclosure - Accounting Principles (Tables)", "shortName": "Accounting Principles (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables", "longName": "30403 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position (Tables)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables", "longName": "30503 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) (Tables)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:RevenueAndOtherIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables", "longName": "30603 - Disclosure - Other financial information (Tables)", "shortName": "Other financial information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "longName": "40101 - Disclosure - Company information (Details)", "shortName": "Company information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_dei_AdrMember_9IbokuFgC0edt5cCkZdvdQ", "name": "ifrs-full:NumberOfSharesRepresentedByOneDepositaryReceipt", "unitRef": "Unit_Standard_pure_CqjweuKaUkKkP8bSO7iYzA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "iva:CompanyInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R23": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "longName": "40102 - Disclosure - Company information - Combined transaction (Details)", "shortName": "Company information - Combined transaction (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProceedsFromIssuingShares", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_2_2026_ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_dei_AdrMember_iva_IfrsSaleOfStockAxis_iva_EquityOfferingMember_CLrekt7SFES0bHO1dJzR7A", "name": "ifrs-full:NumberOfSharesRepresentedByOneDepositaryReceipt", "unitRef": "Unit_Standard_pure_CqjweuKaUkKkP8bSO7iYzA", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R24": { "role": "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "longName": "40103 - Disclosure - Company information - Debt Financing Transactions (Details)", "shortName": "Company information - Debt Financing Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_2_2026_To_6_2_2026_ifrs-full_BorrowingsByNameAxis_iva_BorrowingsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember_HaVtwvN5mU2x7wBNQCXiMA", "name": "iva:MinimumSpecifiedSecuredAccountsAmount", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R25": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "longName": "40201 - Disclosure - Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details)", "shortName": "Basis of preparation and statement of compliance - Significant investments in subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_t7P3PHyKEUuxe9ftXVb-_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:NumberOfEntitiesBeingConsolidated", "unitRef": "Unit_Standard_entity_t7P3PHyKEUuxe9ftXVb-_g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ifrs-full:DisclosureOfInterestsInSubsidiariesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "longName": "40202 - Disclosure - Basis of preparation and statement of compliance - Foreign exchange rates (Details)", "shortName": "Basis of preparation and statement of compliance - Foreign exchange rates (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:AverageForeignExchangeRate", "unitRef": "Unit_Divide_USD_EUR_3vX4REp9vkmAJ1tZO2pT0g", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "longName": "40301 - Disclosure - Accounting principles - Fair value measurement (Details)", "shortName": "Accounting principles - Fair value measurement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_asdU7744Ak2cfc4GuI3kig", "name": "ifrs-full:FinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R28": { "role": "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "longName": "40302 - Disclosure - Accounting principles - Going concern (Details)", "shortName": "Accounting principles - Going concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_10_14_2024_To_10_14_2024_ifrs-full_BorrowingsByNameAxis_iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheCMember_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_SXaLD6tuqkOoliTp-vQxmw", "name": "iva:PotentialProceedsFromDebtFinancing", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R29": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "longName": "40401 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Intangible assets and Property, plant and equipment (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Intangible assets and Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "iva:DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R30": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "longName": "40402 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Investments accounted for using the equity method (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Investments accounted for using the equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:DilutionGainLossOfAssociatesAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "i", "link:footnote", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_2_24_2026_To_2_24_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_-YEq2yFMYEa3jvlBB-Q9BA", "name": "iva:NetProceedsFromIssuingShares", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R31": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "longName": "40403 - Disclosure - Notes to the unaudited interim condensed consolidated statement of (income) loss - Investment in Hepalys is accounted for using the equity method (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of (income) loss - Investment in Hepalys is accounted for using the equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:NoncurrentAssets", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_sUdUXuGyP06_Fv1kOMqQfg", "name": "iva:EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R32": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails", "longName": "40404 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Advances payments - non-current (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Advances payments - non-current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:LongtermDeposits", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherNoncurrentAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails", "longName": "40405 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Trade Receivables (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Trade Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:TradeAndOtherCurrentReceivables", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:CurrentTradeReceivablesAveragePaymentPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R34": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails", "longName": "40406 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Tax receivables and Other current assets (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Tax receivables and Other current assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:CirAndOtherResearchTaxCreditsReceivable", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentAssetsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "longName": "40407 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Other (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Other (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:CurrentTaxAssetsCurrent", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:CirReceivableRelatingToPriorPeriods", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R36": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails", "longName": "40408 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Cash and Cash equivalents balance from the statement of cash flows (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Cash and Cash equivalents balance from the statement of cash flows (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfCashAndCashEquivalentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "longName": "40409 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Shareholders' Equity (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Shareholders' Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R38": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "longName": "40410 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Shareholders' equity - Changes in share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:Equity", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_14_2026_To_1_14_2026_iva_IfrsClassOfWarrantOrRightAxis_iva_T1BisBsaWarrantsMember_iva_IfrsSaleOfStockAxis_iva_FinancingArrangementInThreeTranches2024TrancheIMember_ZydtZi0IPkGYnTY4laWN8Q", "name": "ifrs-full:IncreaseDecreaseInNumberOfSharesOutstanding", "unitRef": "Unit_Standard_shares_lny2FCpc4kWrlSw2EbyjQg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R39": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails", "longName": "40411 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Liquidity agreement (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Liquidity agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": null, "uniqueAnchor": null }, "R40": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "longName": "40412 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Movements in BSPCE and BSA share warrants (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Movements in BSPCE and BSA share warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_DHW6ij5Me0WM4JeM1WatvA", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_OK_B_3pyXkebT7nbSUcXtQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BspceAndBsaShareWarrantsMember_DHW6ij5Me0WM4JeM1WatvA", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "unitRef": "Unit_Standard_EquityInstruments_OK_B_3pyXkebT7nbSUcXtQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "longName": "40413 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Movements in AGA (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Movements in AGA (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_iva_BonusShareAwardPlansMember_GmdXLS9BGUilNa27V2Ppzw", "name": "iva:NumberOfPlansOutstanding", "unitRef": "Unit_Standard_plan_fM62TA0ILUKHPKR5tDOQBg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R42": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails", "longName": "40414 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Stock Options (SO) (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Stock Options (SO) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_LN96kvq9l0-2chV8KE7nrw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "Unit_Standard_Options_LN96kvq9l0-2chV8KE7nrw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "longName": "40415 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Forward contract relating to the New EIB Warrants (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Forward contract relating to the New EIB Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2026_iva_IfrsClassOfWarrantOrRightAxis_iva_NewEuropeanInvestmentBankWarrantsMember_UJNxwCrrWEeebl2AIdn9iw", "name": "iva:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "unitRef": "Unit_Divide_EUR_shares_ZvhVSgnMPUWEuxNQZrT65w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_iva_IfrsClassOfWarrantOrRightAxis_iva_NewEuropeanInvestmentBankWarrantsMember_UJNxwCrrWEeebl2AIdn9iw", "name": "iva:IfrsClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_lny2FCpc4kWrlSw2EbyjQg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "iva:ScheduleOfValuationApproachForEuropeanInvestmentBankWarrantsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R44": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "longName": "40416 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Debt, Derivatives and Royalty Certificates liabilities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Debt, Derivatives and Royalty Certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:LoansReceived", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "longName": "40417 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Changes in liabilities arising from financing activities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Changes in liabilities arising from financing activities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "longName": "40418 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - French state-guaranteed loan (\"PGE\") and equity recovery loans (\"PPR\") (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProceedsFromBorrowingsClassifiedAsFinancingActivities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2022_To_6_30_2022_ifrs-full_BorrowingsByNameAxis_iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember_x0R0aitnskirPLsuCLju2A", "name": "iva:NumberOfLoanAgreements", "unitRef": "Unit_Standard_loan_v_1kyCUvqEKmqEJUj2UOhQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R47": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "longName": "40419 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Credit facility agreement with the European Investment Bank (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Credit facility agreement with the European Investment Bank (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_5_16_2022_To_5_16_2022_ifrs-full_BorrowingsByNameAxis_iva_FinanceContractWithEuropeanInvestmentBankMember_nT06a3A8RU2f9vyXskemHA", "name": "iva:NumberOfEqualTranches", "unitRef": "Unit_Standard_tranche_sOkeHE1fdUyYTFogrwoT9w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R48": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "longName": "40420 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Lease liabilities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Lease liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:LeaseLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:IncreaseDecreaseInLeaseLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R49": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "longName": "40421 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Long-term Derivatives (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Long-term Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:DerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_1_2022_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_LongTermFinancialDebtDerivativesMember_iva_IfrsClassOfWarrantOrRightAxis_iva_EuropeanInvestmentBankWarrantsMember_ZXGjn4VOc0Ovi1M2rZaOkA", "name": "iva:WarrantsSubscriptionPrice", "unitRef": "Unit_Divide_EUR_shares_ZvhVSgnMPUWEuxNQZrT65w", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R50": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "longName": "40422 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Long-term Derivatives - Warrants (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Long-term Derivatives - Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:DerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_6_1_2026_To_6_1_2026_iva_IfrsClassOfWarrantOrRightAxis_iva_EuropeanInvestmentBankWarrantsMember_IxdRCPcx-UyaTdT-EuKRag", "name": "iva:CappedCashPaymentInCaseReplacementWarrantsAreNotIssued", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R51": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails", "longName": "40423 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Short-term Derivative (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Short-term Derivative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_5_14_2025_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_T2NewSharesAndT2BsasCallOptionsMember_1ABS1MnudEWQDwjSMat_zw", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_5_14_2025_ifrs-full_ClassesOfFinancialInstrumentsAxis_iva_T2NewSharesAndT2BsasCallOptionsMember_1ABS1MnudEWQDwjSMat_zw", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "longName": "40424 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Royalty Certificates liabilities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Royalty Certificates liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:Borrowings", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ifrs-full_ClassesOfFinancialLiabilitiesAxis_iva_RoyaltyCertificateLiabilitiesMember_ifrs-full_UnobservableInputsAxis_ifrs-full_DiscountRateMeasurementInputMember_4A_q6baYakeI13YzVzlBDw", "name": "ifrs-full:SignificantUnobservableInputLiabilities", "unitRef": "Unit_Standard_pure_CqjweuKaUkKkP8bSO7iYzA", "xsiNil": "false", "lang": null, "decimals": "1", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R53": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails", "longName": "40425 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Provisions (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:OtherShorttermProvisions", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:AdditionalProvisionsOtherShortTermProvisions", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherProvisionsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R54": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionNetProvisionDetails", "longName": "40426 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Net provision (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:DefinedBenefitObligationAtPresentValue", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInNetProvisionDetails", "longName": "40427 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Changes in the net provision (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Changes in the net provision (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2025_RwgeBFagQkiPy15U9eeCwg", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R56": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails", "longName": "40428 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Breakdown of expense recognized for the period (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Breakdown of expense recognized for the period (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:CurrentServiceCostDefinedBenefitPlans", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails", "longName": "40429 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Other current and non-current liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:EmployeeRelatedPayables", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ifrs-full:DisclosureOfOtherCurrentLiabilitiesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "longName": "40430 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Additional information (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Additional information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:OtherNoncurrentLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:IfrsIncreaseDecreaseInOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R59": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesDetails", "longName": "40431 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Trade payables (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Trade payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "iva:TradePayablesAndOtherCurrentLiabilities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R60": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "longName": "40432 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Trade payables break down (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Trade payables break down (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:TradeAndOtherCurrentPayables", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R61": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "longName": "40433 - Disclosure - Notes to the unaudited interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)", "shortName": "Notes to the unaudited interim condensed consolidated statement of financial position - Financial assets and liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:FinancialAssets", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:FinancialAssetsAtFairValue", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R62": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "longName": "40501 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Revenues and other income (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Revenues and other income (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:RevenueFromContractsWithCustomers", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:Revenue", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "iva:RevenueAndOtherIncomeTableTextBlock", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R63": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "longName": "40503 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Operating expenses (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Operating expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:Studies", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "iva:Studies", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfExpensesExplanatory", "iva:DisclosureOfComponentsOfIncomeStatementTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "longName": "40504 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Personnel costs and headcount (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Personnel costs and headcount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:WagesAndSalaries", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails", "longName": "40505 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Other operating income and expenses (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Other operating income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:GainsOnDisposalsOfInvestments", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:GainsOnDisposalsOfInvestments", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "longName": "40506 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Additional Information (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ExpenseOfRestructuringActivities", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R67": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "longName": "40507 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Financial income and expenses (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Financial income and expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:InterestIncomeOnCashAndCashEquivalents", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:FinancialIncomeAndExpensesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "longName": "40508 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Share of net profit - Equity method (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Share of net profit - Equity method (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:GeneralAndAdministrativeExpense", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_ifrs-full_SignificantInvestmentsInAssociatesAxis_iva_HepalysPharmaIncMember_YwRc5Imhnk2NYK-XS2nKyg", "name": "iva:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "iva:DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } }, "R69": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails", "longName": "40509 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Income tax (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Income tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "longName": "40510 - Disclosure - Notes to the interim condensed consolidated statement of income (loss) - Basic and diluted loss per share (Details)", "shortName": "Notes to the interim condensed consolidated statement of income (loss) - Basic and diluted loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "Duration_1_1_2026_To_6_30_2026_3ek1yG6ACkiD8q89TvN1ug", "name": "ifrs-full:ProfitLoss", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": null }, "R71": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails", "longName": "40601 - Disclosure - Other financial information - Commitments given and received (Details)", "shortName": "Other financial information - Commitments given and received (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2026_ZsSbSXHtTE2Jb2lNXBq1ew", "name": "ifrs-full:ContractualCapitalCommitments", "unitRef": "Unit_Standard_EUR_-NiFNssd3UuhiweoF9lH8A", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "b", "p", "td", "tr", "table", "ifrs-full:DisclosureOfCommitmentsExplanatory", "iva:DisclosureOfOtherFinancialInformationTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails", "longName": "40602 - Disclosure - Other financial information - Financial risk management (Details)", "shortName": "Other financial information - Financial risk management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_7_9_2026_To_7_9_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_IssuanceOfWarrantsMember_iva_IfrsClassOfWarrantOrRightAxis_iva_NewEuropeanInvestmentBankWarrantsMember_nBz0k3X7pEiCCslPud0bXw", "name": "iva:NumberOfWarrantsIssued", "unitRef": "Unit_Standard_shares_lny2FCpc4kWrlSw2EbyjQg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_31_2026_To_8_31_2026_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_iva_AppointmentOfOfficerMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_l2IkRjMfSUqvtjW8qOJvYw", "name": "iva:ExperienceInPharmaceuticalIndustry", "unitRef": "Unit_Standard_Y_zDo6hcs8_EikS2R4jp2iSA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "iva-20260630xex99d1.htm", "unique": true } } }, "tag": { "iva_AccountingPrinciplesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccountingPrinciplesAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Accounting principles" } } }, "auth_ref": [] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Accruals classified as current", "terseLabel": "Accrued expenses" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r355" ] }, "iva_AccrualsClassifiedAsCurrentRelatingToScientificProjects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccrualsClassifiedAsCurrentRelatingToScientificProjects", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accruals classified as current relating to scientific projects", "label": "Accruals classified as current relating to scientific projects", "terseLabel": "Accrued liabilities relating to scientific projects" } } }, "auth_ref": [] }, "iva_AccruedIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccruedIncomeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued income.", "label": "Current accrued income", "terseLabel": "Current accrued income" } } }, "auth_ref": [] }, "iva_AccruedInterestOnBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccruedInterestOnBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents accrued interest on borrowings.", "label": "Accrued interest on borrowings [Member]", "terseLabel": "Accrued interest payable on loans" } } }, "auth_ref": [] }, "iva_AccruedInterestPayableOnLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccruedInterestPayableOnLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for accrued interest payable on loans.", "label": "Accrued interest payable on loans [Member]", "terseLabel": "Accrued interest payable on loans" } } }, "auth_ref": [] }, "iva_AccruedPayrollAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AccruedPayrollAndOtherEmployeeRelatedTaxes", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to accrued payroll and other employee related taxes.", "label": "Accrued payroll and other employeerelated taxes", "terseLabel": "Accrued payroll and other employee-related taxes" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Amortization and impairment" } } }, "auth_ref": [ "r7", "r10", "r35", "r40", "r43", "r176", "r193", "r198", "r201" ] }, "iva_AdditionalProceedsReceivableUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdditionalProceedsReceivableUponExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of additional proceeds receivable upon exercise of warrants.", "label": "Additional Proceeds Receivable Upon Exercise Of Warrants", "terseLabel": "Additional proceeds receivable upon exercise of warrants" } } }, "auth_ref": [] }, "ifrs-full_AdditionalProvisionsOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionalProvisionsOtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Additional provisions, other provisions", "terseLabel": "Additions" } }, "en": { "role": { "documentation": "The amount of additional other provisions made. [Refer: Other provisions]" } } }, "auth_ref": [ "r32", "r190" ] }, "iva_AdditionalProvisionsOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdditionalProvisionsOtherShortTermProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional other provisions made, classified as short-term.", "label": "Additional Provisions, Other Short-Term Provisions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions other than through business combinations, property, plant and equipment including right-of-use assets", "terseLabel": "Additions other than through business combinations, property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment including right-of-use assets other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r329" ] }, "ifrs-full_AdjustedWeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustedWeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate diluted loss per share" } }, "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r26" ] }, "iva_AdjustmentsForCostOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForCostOfDebt", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for cost of debt.", "label": "Adjustments for cost of debt", "negatedLabel": "Cost of debt" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "verboseLabel": "Variation of prepaid expenses" } }, "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease / (increase) in operating and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } } }, "auth_ref": [ "r339" ] }, "iva_AdjustmentsForDepreciationAmortisationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForDepreciationAmortisationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for depreciation, amortisation expense and provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Depreciation, Amortisation and Provisions", "terseLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "iva_AdjustmentsForDilutionGainLossFromInvestmentInAssociateUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForDilutionGainLossFromInvestmentInAssociateUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for dilution gain (loss) of investments accounted for using the equity method to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Dilution Gain (Loss) from Investment in Associate using Equity Method", "terseLabel": "Dilution gain on investment in associate" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForFairValueGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForFairValueGainsLosses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for fair value losses (gains)", "terseLabel": "Fair value variation through profit and loss" } } }, "auth_ref": [ "r338" ] }, "iva_AdjustmentsForGainLossOnLeaseModification": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForGainLossOnLeaseModification", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss) on lease modifications to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments for Gain (Loss) on Lease Modification", "terseLabel": "Gain on lease modification" } } }, "auth_ref": [] }, "iva_AdjustmentsForGainsLossesOnDisposalOfTangibleAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForGainsLossesOnDisposalOfTangibleAndIntangibleAssets", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for gain (loss) on disposals of tangible and intangible assets to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Gains (Losses)On Disposal Of Tangible and Intangible Assets", "negatedLabel": "Net book value of tangible and intangible assets disposed" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "Deferred and current taxes" } } }, "auth_ref": [ "r49" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "verboseLabel": "Increase / (decrease) in operating and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } } }, "auth_ref": [ "r339" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Elimination of non-cash or non-operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Share-based compensation expense" } } }, "auth_ref": [ "r338" ] }, "iva_AdjustmentsForTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdjustmentsForTaxCredits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Adjustments for tax credit to reconcile profit (loss) to net cash flow from (used in) operating activities.", "label": "Adjustments For Tax Credits", "terseLabel": "Tax credits" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForUndistributedProfitsOfAssociates": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUndistributedProfitsOfAssociates", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for undistributed profits of associates", "negatedLabel": "Share of net loss (profit) of associates and joint ventures accounted for using the equity method" } } }, "auth_ref": [ "r338" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Exchange (gains) / losses" } } }, "auth_ref": [ "r293", "r338" ] }, "dei_AdrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AdrMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "ADR [Member]", "terseLabel": "ADS", "documentation": "American Depositary Receipt (or American Depositary Share, ADS)." } } }, "auth_ref": [ "r327" ] }, "iva_AdvancePaymentRecoverableFromDebtFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AdvancePaymentRecoverableFromDebtFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of advance payment made in connection with debt financing that is contractually recoverable upon final repayment of the related financing.", "label": "Advance Payment Recoverable from Debt Financing", "terseLabel": "Advance payment recoverable from debt financing" } } }, "auth_ref": [] }, "iva_Aga20231Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20231Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for New bonus share award plans (AGA 2023-2).", "label": "AGA 2023-1 [Member]", "terseLabel": "AGA 2023-1" } } }, "auth_ref": [] }, "iva_Aga20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20241Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-1.", "label": "AGA 2024-1 [Member]", "terseLabel": "AGA 2024-1" } } }, "auth_ref": [] }, "iva_Aga20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20242Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-2.", "label": "AGA 2024-2 [Member]", "terseLabel": "AGA 2024-2" } } }, "auth_ref": [] }, "iva_Aga20243Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20243Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-3.", "label": "AGA 2024-3 [Member]", "terseLabel": "AGA 2024-3" } } }, "auth_ref": [] }, "iva_Aga20244Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20244Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2024-4.", "label": "AGA 2024-4 [Member]", "terseLabel": "AGA 2024-4" } } }, "auth_ref": [] }, "iva_Aga20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20251Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-1.", "label": "AGA 2025-1 [Member]", "terseLabel": "AGA 2025-1" } } }, "auth_ref": [] }, "iva_Aga20251Tr4Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20251Tr4Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-1 (Tr4).", "label": "AGA 2025-1 (Tr4) [Member]", "terseLabel": "AGA 2025-1 (Tr4)" } } }, "auth_ref": [] }, "iva_Aga20251Tranche13Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20251Tranche13Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-1, Tranche 1-3.", "label": "AGA 2025-1, Tranche 1-3 [Member]", "terseLabel": "AGA 2025-1 (Tr1 - Tr2 - Tr3)" } } }, "auth_ref": [] }, "iva_Aga20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20252Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-2.", "label": "AGA 2025-2 [Member]", "terseLabel": "AGA 2025-2" } } }, "auth_ref": [] }, "iva_Aga20254Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20254Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-4.", "label": "AGA 2025-4 [Member]", "terseLabel": "AGA 2025-4" } } }, "auth_ref": [] }, "iva_Aga20255Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20255Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2025-5.", "label": "AGA 2025-5 [Member]", "terseLabel": "AGA 2025-5" } } }, "auth_ref": [] }, "iva_Aga20261BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20261BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2026-1 bis.", "label": "AGA 2026-1 Bis [Member]", "terseLabel": "AGA 2026-1 bis" } } }, "auth_ref": [] }, "iva_Aga20261Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20261Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2026-1.", "label": "AGA 2026-1 [Member]", "terseLabel": "AGA 2026-1" } } }, "auth_ref": [] }, "iva_Aga20262BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20262BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2026-2 bis.", "label": "AGA 2026-2 Bis [Member]", "terseLabel": "AGA 2026-2 bis" } } }, "auth_ref": [] }, "iva_Aga20262Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Aga20262Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for AGA 2026-2.", "label": "AGA 2026-2 [Member]", "terseLabel": "AGA 2026-2" } } }, "auth_ref": [] }, "iva_AgaAndBsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AgaAndBsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents AGA and BSA share-based payment plans.", "label": "AGA and BSA plans [member]", "terseLabel": "AGA and BSA plans" } } }, "auth_ref": [] }, "iva_AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AggregateAmountToBeReceivedEitherInExchangeForNewSharesOrWarrantsOfCompany", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Aggregate amount to be received by the company, either in exchange for new shares or warrants of the Company.", "label": "Aggregate Amount To Be Received Either In Exchange For New Shares or Warrants Of The Company", "terseLabel": "Structured Financing amount" } } }, "auth_ref": [] }, "iva_AggregateRepurchasePriceOfFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AggregateRepurchasePriceOfFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of aggregate repurchases price of financial liabilities.", "label": "Aggregate Repurchase Price of Financial Liabilities", "terseLabel": "Warrant issued at aggregate repurchase price" } } }, "auth_ref": [] }, "iva_AgreementsForProvisionOfFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AgreementsForProvisionOfFacilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for agreements for provision of facilities.", "label": "Agreements for provision of facilities [Member]", "terseLabel": "Agreements concerning the provision of facilities" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "iva_AppointmentOfOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AppointmentOfOfficerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for appointment of officer.", "label": "Appointment Of Officer [Member]", "terseLabel": "Appointment of Officer" } } }, "auth_ref": [] }, "iva_ArrangementFeePerWarrant": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ArrangementFeePerWarrant", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "documentation": "Arrangement fee per warrant.", "label": "Arrangement fee per warrant" } } }, "auth_ref": [] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total assets" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r79", "r80", "r82", "r135", "r139", "r228", "r229", "r255" ] }, "iva_AtMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AtMarketOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for at-the market offering (ATM).", "label": "At Market Offering [Member]", "terseLabel": "ATM" } } }, "auth_ref": [] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [axis]" } } }, "auth_ref": [ "r346", "r349" ] }, "ifrs-full_AttributionOfExpensesByNatureToTheirFunctionDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AttributionOfExpensesByNatureToTheirFunctionDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Attribution of expenses by nature to their function [domain]" } } }, "auth_ref": [ "r346", "r349" ] }, "ifrs-full_AverageEffectiveTaxRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageEffectiveTaxRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Average effective tax rate" } }, "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } } }, "auth_ref": [ "r3", "r172" ] }, "ifrs-full_AverageForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "AverageForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average exchange rate for the period" } }, "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } } }, "auth_ref": [ "r349" ] }, "iva_AxelSvenMalkomesChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "AxelSvenMalkomesChiefFinancialOfficerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Axel-Sven Malkomes, Chief Financial Officer.", "label": "Axel-Sven Malkomes, Chief Financial Officer [Member]", "terseLabel": "Axel-Sven Malkomes, Chief Financial Officer" } } }, "auth_ref": [] }, "iva_BankBorrowingsAndRelatedDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BankBorrowingsAndRelatedDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents bank borrowings and related derivatives.", "label": "Bank borrowings and related derivatives [Member]", "terseLabel": "Bank borrowings including interests" } } }, "auth_ref": [] }, "iva_BankBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BankBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bank borrowings.", "label": "Bank Borrowings [Member]", "terseLabel": "Total Bank Borrowings", "verboseLabel": "Bank Borrowings" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r24", "r25" ] }, "iva_BasisOfPreparationAndStatementOfComplianceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BasisOfPreparationAndStatementOfComplianceTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfCompliance" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for basis of preparation and statement of compliance.", "label": "Basis of preparation and statement of compliance [text block]", "terseLabel": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "iva_BonusShareAwardPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BonusShareAwardPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for bonus share award plans.", "label": "Bonus Share Award Plans [Member]", "terseLabel": "Bonus share award plans (AGA)", "verboseLabel": "AGA" } } }, "auth_ref": [] }, "ifrs-full_BorrowingCostsIncurred": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingCostsIncurred", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Borrowing costs incurred", "terseLabel": "Borrowing costs" } }, "en": { "role": { "documentation": "The amount of interest and other costs that an entity incurs in connection with the borrowing of funds." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails": { "parentTag": "iva_DebtFinancial", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings", "terseLabel": "Borrowings", "verboseLabel": "Debt" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r352" ] }, "ifrs-full_BorrowingsByNameAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r344" ] }, "ifrs-full_BorrowingsByNameDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsByNameDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings by name [domain]" } }, "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "auth_ref": [ "r344" ] }, "iva_BorrowingsEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BorrowingsEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The effective interest rate on borrowings.", "label": "Borrowings, effective interest rate", "terseLabel": "Borrowings, effective interest rate" } } }, "auth_ref": [] }, "iva_BorrowingsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BorrowingsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents borrowings from 2026 Debt Financing Transaction with BlackRock and Claret Capital", "label": "Borrowings from 2026 Debt Financing Transaction with BlackRock and Claret Capital [member]", "terseLabel": "Borrowings from 2026 Debt Financing Transaction with BlackRock and Claret Capital" } } }, "auth_ref": [] }, "ifrs-full_BorrowingsInterestRate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BorrowingsInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate" } }, "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r344" ] }, "iva_BorrowingsMaximumExtensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BorrowingsMaximumExtensionTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Period up to which the maturity term of the borrowings can be extended.", "label": "Borrowings, Maximum Extension Term", "verboseLabel": "Extension of term of debt" } } }, "auth_ref": [] }, "iva_BorrowingsPaymentInKindInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BorrowingsPaymentInKindInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The payment-in-kind interest rate on borrowings.", "label": "Borrowings, Payment In Kind, Interest Rate", "terseLabel": "Interest rate", "verboseLabel": "Payment in kind Interest" } } }, "auth_ref": [] }, "ifrs-full_BottomOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "BottomOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Minimum" } }, "en": { "role": { "documentation": "This member stands for the bottom of a range." } } }, "auth_ref": [ "r53", "r83", "r94", "r103", "r166", "r297", "r299", "r344" ] }, "iva_Bsa2017PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bsa2017PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2017 plan.", "label": "BSA - 2017 plan" } } }, "auth_ref": [] }, "iva_Bsa2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bsa2018PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA - 2018 plan.", "label": "BSA - 2018 plan" } } }, "auth_ref": [] }, "iva_Bsa20231ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bsa20231ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-1 share warrants plan.", "label": "BSA 2023-1 Share Warrant Plan [Member]", "terseLabel": "BSA 2023-1" } } }, "auth_ref": [] }, "iva_Bsa20232ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bsa20232ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2023-2 share warrants plan.", "label": "BSA 2023-2 Share Warrant Plan [Member]", "terseLabel": "BSA- 2 2023 plan" } } }, "auth_ref": [] }, "iva_Bsa2026WarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bsa2026WarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA 2026 warrant plan.", "label": "BSA 2026 Warrant Plan [Member]", "terseLabel": "BSA 2026" } } }, "auth_ref": [] }, "iva_BsaPlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BsaPlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSA plans.", "label": "BSA plans" } } }, "auth_ref": [] }, "iva_Bspce2021PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Bspce2021PlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE 2021 plan.", "label": "BSPCE 2021" } } }, "auth_ref": [] }, "iva_BspceAndBsaShareWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BspceAndBsaShareWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE and BSA share warrants.", "label": "BSPCE and BSA Share Warrants", "verboseLabel": "BSPCE share warrants and BSA share warrants" } } }, "auth_ref": [] }, "iva_BspcePlansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "BspcePlansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for BSPCE plans.", "label": "BSPCE plans" } } }, "auth_ref": [] }, "country_CN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2025", "localname": "CN", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "auth_ref": [] }, "iva_CappedCashPaymentInCaseReplacementWarrantsAreNotIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CappedCashPaymentInCaseReplacementWarrantsAreNotIssued", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Capped cash payment in case replacement warrants are not issued.", "label": "Capped cash payment in case replacement warrants are not issued" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r7", "r8", "r35", "r36", "r39", "r40", "r41", "r42", "r43", "r109", "r115", "r116", "r176", "r177", "r193", "r194", "r197", "r198", "r199", "r200", "r201", "r211", "r220", "r221" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount [member]" } } }, "auth_ref": [ "r8", "r36", "r39", "r41", "r42", "r109", "r115", "r116", "r177", "r194", "r197", "r199", "r200", "r211", "r220", "r221" ] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Cash", "terseLabel": "Cash at bank and at hand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Net cash and cash equivalents at the end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r54", "r72", "r167", "r250" ] }, "ifrs-full_CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashAndCashEquivalentsIfDifferentFromStatementOfFinancialPosition", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents if different from statement of financial position", "totalLabel": "Cash and cash equivalents balance from the statement of cash flows" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents in the statement of cash flows when different from the amount of cash and cash equivalents in the statement of financial position. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInDecreaseIncreaseInShorttermDepositsAndInvestments", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) decrease (increase) in short-term deposits and investments", "terseLabel": "Decrease / (Increase) in short-term deposit accounts" } }, "en": { "role": { "documentation": "The cash inflow (outflow) due to a decrease (increase) in short-term deposits and investments." } } }, "auth_ref": [ "r336" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash flows provided by (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r44", "r55" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows provided by (used in) financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash flows provided by (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r44", "r55" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows provided by (used in) investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "auth_ref": [ "r44", "r55" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Cash flows used in operations before tax and changes in working capital" } }, "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } } }, "auth_ref": [ "r293", "r339" ] }, "iva_CashUnderLiquidityAgreementCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CashUnderLiquidityAgreementCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash under liquidity agreement, classified as current.", "label": "Cash Under Liquidity Agreement, Current", "terseLabel": "Liquidity agreement - Cash" } } }, "auth_ref": [] }, "iva_CatalysOptionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CatalysOptionAgreementMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Catalys Option Agreement.", "label": "Catalys Option Agreement [Member]", "terseLabel": "Catalys Option Agreement" } } }, "auth_ref": [] }, "iva_CatchUpAdjustmentForRepaymentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CatchUpAdjustmentForRepaymentOfDebt", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of catch-up adjustment to reflect the revised cash flow for repayment of debt.", "label": "Catch Up Adjustment For Repayment Of Debt", "verboseLabel": "Catch-up adjustment to reflect the revised cash flow" } } }, "auth_ref": [] }, "iva_CatchUpAdjustmentFromUnwindingOfDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CatchUpAdjustmentFromUnwindingOfDiscount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of catch-up adjustment arising from unwinding of discount.", "label": "Catch Up Adjustment From Unwinding Of Discount", "verboseLabel": "Catch-up adjustment arising from unwinding of discount" } } }, "auth_ref": [] }, "iva_CatchUpImpactOfDebtUponRemeasurement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CatchUpImpactOfDebtUponRemeasurement", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of aggregate catch-up impact including adjustment for cash flows and unwinding of discount of debt upon remeasurement.", "label": "Catch Up Impact Of Debt Upon Remeasurement", "negatedLabel": "Catch-up impact of the EIB debt remeasurement" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r129", "r216" ] }, "ifrs-full_CategoriesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialAssetsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial assets. It also represents the standard value for the 'Categories of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r129", "r216" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r129", "r216" ] }, "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Categories of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r129", "r216" ] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r18", "r183" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r18", "r183" ] }, "srt_ChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ChiefOperatingOfficerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]", "terseLabel": "Chief Operating Officer" } } }, "auth_ref": [] }, "iva_CirAndOtherResearchTaxCreditsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CirAndOtherResearchTaxCreditsReceivable", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of CIR and other research tax credits receivable.", "label": "CIR and Other Research Tax Credits Receivable", "terseLabel": "CIR and other research tax credits" } } }, "auth_ref": [] }, "iva_CirReceivableRelatingToCurrentPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CirReceivableRelatingToCurrentPeriod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "CIR receivable relating to current period.", "label": "CIR receivable relating to current period" } } }, "auth_ref": [] }, "iva_CirReceivableRelatingToPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CirReceivableRelatingToPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of CIR receivable relating to prior period.", "label": "CIR Receivable Relating To Prior Periods", "terseLabel": "CIR receivable relating to prior period" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRepurchasedAndCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRepurchasedAndCancelled", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted are repurchased and cancelled.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights, Repurchased and Cancelled", "terseLabel": "Underlying shares" } } }, "auth_ref": [] }, "iva_ClassOfWarrantOrRightSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ClassOfWarrantOrRightSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Subscription price per share or per unit of warrants or rights outstanding.", "label": "Class Of Warrant Or Right, Subscription Price", "terseLabel": "Subscription price per warrant" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r96", "r123", "r124", "r146", "r147", "r237" ] }, "ifrs-full_ClassesOfFinancialAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialAssetsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial assets [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } } }, "auth_ref": [ "r96", "r123", "r124", "r146", "r147", "r237" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r115", "r117", "r119", "r120", "r220", "r223" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r115", "r117", "r119", "r120", "r220", "r223" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r123", "r124", "r146", "r147" ] }, "ifrs-full_ClassesOfFinancialLiabilitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfFinancialLiabilitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Classes of financial liabilities [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r123", "r124", "r146", "r147" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r9", "r178" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r9", "r178" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r161", "r232", "r267" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [domain]" } }, "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r161", "r232", "r267" ] }, "ifrs-full_ClosingForeignExchangeRate": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ClosingForeignExchangeRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Exchange rate at the end of period" } }, "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } } }, "auth_ref": [ "r349" ] }, "iva_ClosureOfShortTermDepositAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ClosureOfShortTermDepositAccount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "Closure of short-term deposit account.", "label": "Closure of short-term deposit account" } } }, "auth_ref": [] }, "iva_CommitmentsGivenAndReceivedAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CommitmentsGivenAndReceivedAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by commitments given and received", "label": "Commitments given and received [Axis]" } } }, "auth_ref": [] }, "iva_CommitmentsGivenAndReceivedDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CommitmentsGivenAndReceivedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Commitments given and received.", "label": "Commitments given and received [Domain]" } } }, "auth_ref": [] }, "iva_CompanyInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CompanyInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Company information." } } }, "auth_ref": [] }, "iva_CompanyInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CompanyInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure on company information.", "label": "Company Information [Text Block]", "terseLabel": "Company information" } } }, "auth_ref": [] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Components of equity [domain]" } }, "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_ComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } } }, "auth_ref": [ "r57", "r59", "r69", "r185", "r203", "r239", "r270", "r295" ] }, "iva_ContractCroWithPharmaceuticalResearchAssociatesB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractCroWithPharmaceuticalResearchAssociatesB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO With Pharmaceutical Research Associates B.V [Member]", "terseLabel": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_ContractCroWithResearchAssociatesGroupeB.vMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractCroWithResearchAssociatesGroupeB.vMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Contract CRO with PRA.", "label": "Contract CRO with Pharmaceutical Research Associates B.V." } } }, "auth_ref": [] }, "iva_ContractManufacturingOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractManufacturingOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Contract Manufacturing Organizations(CMO).", "label": "Contract Manufacturing Organizations [Member]", "terseLabel": "CMO" } } }, "auth_ref": [] }, "iva_ContractResearchOrganizationsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractResearchOrganizationsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Contract research organizations.", "label": "Contract research organizations [Member]", "terseLabel": "CRO" } } }, "auth_ref": [] }, "iva_ContractualCapitalCommitmentReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractualCapitalCommitmentReceived", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contractual capital commitment received.", "label": "Contractual Capital Commitment Received", "terseLabel": "Total commitments received" } } }, "auth_ref": [] }, "ifrs-full_ContractualCapitalCommitments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ContractualCapitalCommitments", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Contractual capital commitments", "terseLabel": "Total commitments given" } }, "en": { "role": { "documentation": "The amount of capital commitments for which the entity has entered into a contract. [Refer: Capital commitments]" } } }, "auth_ref": [ "r349" ] }, "iva_ContractualCommitmentsBonusOrMalusAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ContractualCommitmentsBonusOrMalusAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of bonus or malus amount included in contractual commitments.", "label": "Contractual Commitments, Bonus Or Malus Amount", "terseLabel": "Bonus or malus capped amount" } } }, "auth_ref": [] }, "iva_ConvertibleOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ConvertibleOptionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for convertible option.", "label": "Convertible Option [Member]", "terseLabel": "Convertible option (Convertible Bonds)" } } }, "auth_ref": [] }, "ifrs-full_CounterpartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r131" ] }, "ifrs-full_CounterpartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CounterpartiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Counterparties [domain]" } }, "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "auth_ref": [ "r131" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "iva_CreditAgricoleBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CreditAgricoleBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Credit Agricole Bank.", "label": "Crdit Agricole bank", "terseLabel": "Crdit Agricole bank" } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "CurrencyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAccruedIncomeIncludingCurrentContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAccruedIncomeIncludingCurrentContractAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current accrued income including current contract assets", "terseLabel": "Current accrued income" } }, "en": { "role": { "documentation": "The amount of current accrued income including current contract assets. [Refer: Accrued income including contract assets]" } } }, "auth_ref": [ "r352", "r355" ] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets", "verboseLabel": "Current assets" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r65", "r259", "r295" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "auth_ref": [] }, "iva_CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CurrentBorrowingsAndCurrentPortionOfNonCurrentBorrowingsAndCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "label": "Current borrowings and current portion of non-current borrowings and current lease liabilities", "terseLabel": "Short-term debt" } } }, "auth_ref": [] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails" ], "lang": { "en-us": { "role": { "label": "Current derivative financial liabilities", "verboseLabel": "Derivative liabilities" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r352" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total current liabilities", "verboseLabel": "Current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r67", "r260", "r295" ] }, "ifrs-full_CurrentPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentPrepaidExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current prepaid expenses", "terseLabel": "Prepaid expenses" } }, "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_CurrentServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Current service cost, defined benefit plans", "negatedLabel": "Service cost for the period" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "iva_OtherCurrentAssetsAndTaxReceivables", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current tax assets, current", "terseLabel": "Tax receivables", "totalLabel": "Tax receivables" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r252" ] }, "iva_CurrentTaxCreditResearchIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CurrentTaxCreditResearchIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from tax credit research.", "label": "Current Tax Credit Research Income", "verboseLabel": "CIR" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriods", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Current tax expense (income) and adjustments for current tax of prior periods", "terseLabel": "Current taxes" } } }, "auth_ref": [ "r328" ] }, "iva_CurrentTradeReceivablesAveragePaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "CurrentTradeReceivablesAveragePaymentPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the average payment period for trade receivables.", "label": "Current Trade Receivables, Average Payment Period", "terseLabel": "Average payment period for trade receivables" } } }, "auth_ref": [] }, "ifrs-full_CurrentValueAddedTaxPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "VAT payables" } }, "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } } }, "auth_ref": [ "r355" ] }, "ifrs-full_CurrentValueAddedTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "CurrentValueAddedTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "VAT receivables" } }, "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } } }, "auth_ref": [ "r353" ] }, "iva_DebtFinancial": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DebtFinancial", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt, financial", "label": "Debt, financial", "totalLabel": "Total Debt" } } }, "auth_ref": [] }, "iva_DebtInstrumentConvertibleConversionPricePremium": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DebtInstrumentConvertibleConversionPricePremium", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage premium applied to the applicable reference price to determine the conversion price of the convertible bonds.", "label": "Debt Instrument, Convertible, Conversion Price, Premium", "terseLabel": "Conversion price" } } }, "auth_ref": [] }, "iva_DecreaseInLeaseLiabilitiesThroughRepayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DecreaseInLeaseLiabilitiesThroughRepayments", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in lease liabilities through repayments.", "label": "Decrease in lease liabilities through repayments" } } }, "auth_ref": [] }, "iva_DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughDecreaseInLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughDecreaseInLoans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in liabilities arising from financing activities through decrease in loans", "label": "Decrease in liabilities arising from financing activities through decrease in loans", "negatedLabel": "Decrease in loans" } } }, "auth_ref": [] }, "iva_DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPaymentOfInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPaymentOfInterest", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in liabilities arising from financing activities through payment of interest.", "label": "Decrease in liabilities arising from financing activities through payment of interest", "negatedLabel": "Interest paid" } } }, "auth_ref": [] }, "iva_DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPaymentOfLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPaymentOfLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Decrease in liabilities arising from financing activities through payment of lease liabilities.", "label": "Decrease in liabilities arising from financing activities through payment of lease liabilities", "negatedLabel": "Payment of lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Deferred tax assets", "verboseLabel": "Deferred tax assets" } }, "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } } }, "auth_ref": [ "r4", "r173", "r253", "r256" ] }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss" } } }, "auth_ref": [ "r5", "r174" ] }, "ifrs-full_DefinedBenefitObligationAtPresentValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DefinedBenefitObligationAtPresentValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Defined benefit obligation, at present value", "verboseLabel": "Retirement benefit obligations" } }, "en": { "role": { "documentation": "The present value, without deducting any plan assets, of expected future payments required to settle the obligation resulting from employee service in the current and prior periods. [Refer: Plan assets, at fair value]" } } }, "auth_ref": [ "r333" ] }, "iva_DepreciationAmortizationAndProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DepreciationAmortizationAndProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Depreciation, amortization and provisions expense.", "label": "Depreciation, amortization and provisions", "negatedLabel": "Depreciation, amortization and provisions" } } }, "auth_ref": [] }, "iva_DerivativeAndNonDerivativeFinancialLiabilitiesUndiscountedCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DerivativeAndNonDerivativeFinancialLiabilitiesUndiscountedCashFlows", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Derivative and non-derivative financial liabilities, undiscounted cash flows.", "label": "Derivative and non-derivative financial liabilities, undiscounted cash flows", "terseLabel": "Derivative and non-derivative financial liabilities, undiscounted cash flows" } } }, "auth_ref": [] }, "ifrs-full_DerivativeFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial assets", "terseLabel": "Derivative financial assets" } }, "en": { "role": { "documentation": "The amount of financial assets classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_DerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails": { "parentTag": "iva_DebtFinancial", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial liabilities", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r352" ] }, "iva_DerivativeInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DerivativeInstrumentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for derivative instruments.", "label": "Derivative instruments", "terseLabel": "Derivative instruments" } } }, "auth_ref": [] }, "ifrs-full_DerivativesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Derivatives [member]", "terseLabel": "Derivatives" } }, "en": { "role": { "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r296", "r298", "r304", "r314" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value measurement" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for fair value measurement. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r350" ] }, "iva_DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DescriptionOfAccountingPolicyForSpecificDisclosureRequirementsForUnauditedInterimFinancialStatementsPolicyTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Specific disclosure requirements for unaudited interim financial statements.", "label": "Description Of Accounting Policy For Specific Disclosure Requirements For Unaudited Interim Financial Statements [Policy Text Block]", "terseLabel": "Specific disclosure requirements for unaudited interim financial statements" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DescriptionOfOptionLifeShareOptionsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfOptionLifeShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Option life, share options granted", "terseLabel": "Average life (years)" } }, "en": { "role": { "documentation": "The option life of share options granted." } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r105" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r24", "r25" ] }, "iva_DilutionGainLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DilutionGainLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLossParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount of dilution gain (loss) of associates accounted for using the equity method.", "label": "Dilution Gain (Loss) Of Associates Accounted For Using Equity Method", "terseLabel": "Dilution gain on investment in associate" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgment" } }, "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [line items]", "terseLabel": "Operating expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfAttributionOfExpensesByNatureToTheirFunctionTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of attribution of expenses by nature to their function [table]" } } }, "auth_ref": [ "r346", "r349" ] }, "iva_DisclosureOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of cash and cash equivalents balance from the statement of cash flows" } } }, "auth_ref": [] }, "iva_DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfChangesInProvisionRecordedInRespectOfDefinedBenefitSchemesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about change in the provision recorded in respect of defined benefit schemes.", "label": "Disclosure Of Changes In Provision Recorded In Respect Of Defined Benefit Schemes, Explanatory", "terseLabel": "Schedule of change in the provision recorded in respect of defined benefit schemes" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [text block]", "terseLabel": "Schedule of changes in share capital" } }, "en": { "role": { "documentation": "The disclosure of classes of share capital. [Refer: Classes of share capital [domain]]" } } }, "auth_ref": [ "r161", "r232", "r267" ] }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfClassesOfShareCapitalTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } } }, "auth_ref": [ "r161", "r232", "r267" ] }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfCommitmentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of commitments [text block]", "verboseLabel": "Schedule of commitments given and received" } }, "en": { "role": { "documentation": "The disclosure of commitments." } } }, "auth_ref": [ "r345" ] }, "iva_DisclosureOfComponentsOfIncomeStatementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfComponentsOfIncomeStatementTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for components of income statement.", "label": "Disclosure Of Components Of Income Statement [Text Block]", "terseLabel": "Notes to the interim condensed consolidated statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDepositaryReceiptsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDepositaryReceiptsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of depositary receipts [line items]", "terseLabel": "Company information" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDepositaryReceiptsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDepositaryReceiptsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of depositary receipts [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information about depositary receipts." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [abstract]" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "verboseLabel": "Schedule of Debt, Derivatives and Royalty Certificates liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r344" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Guarantee Details", "verboseLabel": "Debt, Derivatives and Royalty certificates liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } } }, "auth_ref": [ "r344" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities" } }, "en": { "role": { "documentation": "The disclosure of detailed information about financial instruments. [Refer: Classes of financial instruments [domain]]" } } }, "auth_ref": [ "r113", "r117", "r125", "r212" ] }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of intangible assets" } }, "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r37", "r195" ] }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Schedule of exchange rates" } }, "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } } }, "auth_ref": [ "r17" ] }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfEmployeeBenefitsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "verboseLabel": "Schedule of personnel costs and headcount" } }, "en": { "role": { "documentation": "The entire disclosure for employee benefits." } } }, "auth_ref": [ "r14" ] }, "ifrs-full_DisclosureOfExpensesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfExpensesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of expenses [text block]", "terseLabel": "Schedule of operating expenses" } }, "en": { "role": { "documentation": "The disclosure of expenses." } } }, "auth_ref": [ "r345" ] }, "iva_DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfExpensesRecognizedInStatementOfIncomeLossForRetirementBenefitObligationsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about expense recognized in the statement of income (loss) for Retirement Benefit Obligations.", "label": "Disclosure Of Expenses Recognized In Statement Of Income (Loss) For Retirement Benefit Obligations, Explanatory", "terseLabel": "Schedule of breakdown of expense recognized for the period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Schedule of financial assets and liabilities measured at fair value" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [line items]", "terseLabel": "Foreign currency forwards contract", "verboseLabel": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r113", "r117", "r125", "r212" ] }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfGoingConcernExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesPolicies" ], "lang": { "en-us": { "role": { "label": "Disclosure of going concern [text block]", "terseLabel": "Going concern" } }, "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } } }, "auth_ref": [ "r345" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]", "terseLabel": "Schedule of measurements for share options granted" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r106" ] }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "verboseLabel": "Intangible assets and Property, plant and equipment" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } } }, "auth_ref": [ "r37", "r195" ] }, "ifrs-full_DisclosureOfInterestsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfInterestsInSubsidiariesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of interests in subsidiaries [text block]", "terseLabel": "Schedule of subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of interests in subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r63" ] }, "ifrs-full_DisclosureOfMaterialAccountingPolicyInformationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfMaterialAccountingPolicyInformationExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciples" ], "lang": { "en-us": { "role": { "label": "Disclosure of material accounting policy information [text block]", "terseLabel": "Accounting principles" } }, "en": { "role": { "documentation": "The entire disclosure of material accounting policy information applied by the entity." } } }, "auth_ref": [ "r168", "r233", "r245" ] }, "iva_DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfNotesToInterimCondensedConsolidatedStatementOfFinancialPositionTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for notes to the interim consolidated balance sheet.", "label": "Disclosure of Notes to the Interim Condensed Consolidated Statement of Financial Position [Text Block]", "terseLabel": "Notes to the unaudited interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Schedule of movements in BSPCE and BSA share warrants and AGA" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } } }, "auth_ref": [ "r343" ] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of share options [text block]", "terseLabel": "Schedule of stock option plans" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r101", "r208" ] }, "ifrs-full_DisclosureOfOtherCurrentAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current assets [text block]", "terseLabel": "Schedule of other current assets and receivables" } }, "en": { "role": { "documentation": "The disclosure of other current assets. [Refer: Other current assets]" } } }, "auth_ref": [ "r345" ] }, "ifrs-full_DisclosureOfOtherCurrentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherCurrentLiabilitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other current liabilities [text block]", "terseLabel": "Schedule of other current liabilities" } }, "en": { "role": { "documentation": "The disclosure of other current liabilities. [Refer: Other current liabilities]" } } }, "auth_ref": [ "r345" ] }, "iva_DisclosureOfOtherFinancialInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfOtherFinancialInformationTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformation" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other financial information.", "label": "Disclosure Of Other Financial Information [Text Block]", "terseLabel": "Other financial information" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherNoncurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfOtherNoncurrentAssetsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other non current assets.", "label": "Disclosure Of Other Noncurrent Assets [Table Text Block]", "terseLabel": "Schedule of other non current assets" } } }, "auth_ref": [] }, "iva_DisclosureOfOtherOperatingIncomeExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfOtherOperatingIncomeExpenseTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of other operating income (expense).", "label": "Disclosure Of Other Operating Income Expense [Table Text Block]", "terseLabel": "Schedule of other operating income and expenses" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [text block]", "terseLabel": "Schedule of provisions" } }, "en": { "role": { "documentation": "The disclosure of other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r34", "r192" ] }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Other operating income and expenses" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfOtherProvisionsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of other provisions [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } } }, "auth_ref": [ "r34", "r192" ] }, "iva_DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfProvisionRecordedInRespectOfDefinedBenefitSchemesAtEndOfEachReportingPeriodExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about provision recorded in respect of defined benefit schemes at the end of each reporting period.", "label": "Disclosure Of Provision Recorded In Respect Of Defined Benefit Schemes At End Of Each Reporting Period, Explanatory", "terseLabel": "Schedule of provision recorded in respect of defined benefit schemes at the end of each reporting period" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInPropertyPlantAndEquipmentIncludingRightofuseAssetsExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in property, plant and equipment, including right-of-use assets [text block]", "terseLabel": "Reconciliation of changes in property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in property, plant and equipment, including right-of-use assets." } } }, "auth_ref": [ "r329" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [text block]", "terseLabel": "Schedule of changes in liabilities" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of liabilities arising from financing activities. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r165", "r292" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [line items]", "terseLabel": "Changes in liabilities arising from financing activities" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r165", "r292" ] }, "ifrs-full_DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfSummarisedFinancialInformationOfAssociateAccountedForUsingEquityMethodToCarryingAmountOfInterestInAssociateExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of summarised financial information of associate accounted for using equity method to carrying amount of interest in associate [text block]", "terseLabel": "Schedule of investment in Hepalys is accounted for using the equity method of accounting" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of the summarised financial information of an associate accounted for using the equity method to the carrying amount of the reporting entity's interest in the associate. [Refer: Carrying amount [member]; Total for all associates [member]]" } } }, "auth_ref": [ "r75" ] }, "iva_DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodInvestmentsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of share of profit loss of associates and joint ventures accounted for using equity method investments.", "label": "Disclosure Of Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of share of net profit (loss) - Equity method" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [line items]", "terseLabel": "Investments accounted for using the equity method", "verboseLabel": "Other financial information" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of associates [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to associates." } } }, "auth_ref": [ "r21", "r23", "r78", "r226" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [line items]", "terseLabel": "Basis of preparation and statement of compliance" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r21", "r23", "r77", "r225" ] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "verboseLabel": "Income tax" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } } }, "auth_ref": [ "r6", "r175" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]", "terseLabel": "Schedule of main characteristics of share-based payment plan" } }, "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r104", "r209" ] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "verboseLabel": "Notes to the unaudited interim condensed consolidated statement of financial position" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } } }, "auth_ref": [ "r104", "r209" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Schedule of trade payables break down by payment" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r345" ] }, "iva_DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfTradePayablesAndOtherCurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for trade payables and other current liabilities.", "label": "Disclosure Of Trade Payables and Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_DisclosureOfTradeReceivablesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfTradeReceivablesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of trade receivables.", "label": "Disclosure of Trade Receivables [Table Text Block]", "terseLabel": "Schedule of trade receivables and others break down" } } }, "auth_ref": [] }, "iva_DisclosureOfValuationApproachForEuropeanInvestmentBankWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfValuationApproachForEuropeanInvestmentBankWarrantsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for European Investment Bank warrants.", "label": "Disclosure of valuation approach for European Investment Bank warrants [table text block]", "terseLabel": "Schedule of valuation approach for EIB warrants" } } }, "auth_ref": [] }, "iva_DisclosureOfValuationApproachForLendersWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DisclosureOfValuationApproachForLendersWarrantsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of valuation approach for lenders' warrants.", "label": "Disclosure of valuation approach for lenders' warrants [table text block]", "terseLabel": "Schedule of valuation approach for lenders' warrants" } } }, "auth_ref": [] }, "ifrs-full_DiscountRateMeasurementInputMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DiscountRateMeasurementInputMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate, measurement input [member]", "terseLabel": "Discount rate" } }, "en": { "role": { "documentation": "This member stands for a discount rate used as a measurement input used in valuation techniques based on a present value calculation." } } }, "auth_ref": [ "r341" ] }, "iva_Disposables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Disposables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Disposables expense.", "label": "Disposables", "negatedLabel": "Disposables" } } }, "auth_ref": [] }, "ifrs-full_DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disposals, property, plant and equipment including right-of-use assets", "terseLabel": "Decrease in connection with asset disposals" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment including right-of-use assets resulting from disposals. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r329" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "iva_DrawdownOfBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "DrawdownOfBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for drawdown of borrowings", "label": "Drawdown of borrowings [Member]", "terseLabel": "Drawdown of borrowings" } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "EUR", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EarningsPerShareExplanatory", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of basic and diluted loss per share" } }, "en": { "role": { "documentation": "The disclosure of earnings per share." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Exchange gains / (losses)" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r46", "r47" ] }, "iva_EliminationOfDownstreamSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EliminationOfDownstreamSales", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of elimination of downstream sales.", "label": "Elimination Of Downstream Sales", "negatedLabel": "Elimination of downstream sales" } } }, "auth_ref": [] }, "iva_EmbeddedDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EmbeddedDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for embedded derivatives.", "label": "Embedded Derivatives [Member]", "terseLabel": "Embedded derivatives" } } }, "auth_ref": [] }, "ifrs-full_EmployeeBenefitsExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EmployeeBenefitsExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 3.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Employee benefits expense", "negatedTerseLabel": "Personnel costs", "negatedTotalLabel": "Total personnel costs" } } }, "auth_ref": [ "r158", "r238", "r278", "r318" ] }, "iva_EmployeeRelatedPayables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EmployeeRelatedPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the amount pertaining to employee related payables.", "label": "Employee related payables", "verboseLabel": "Employee-related payables" } } }, "auth_ref": [] }, "iva_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EmployeesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for employees.", "label": "Employees" } } }, "auth_ref": [] }, "iva_EnergyAndLiquids": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EnergyAndLiquids", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Energy and liquids expense.", "label": "Energy and liquids", "negatedLabel": "Energy and liquids" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r326" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "All Entities [Member]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://www.inventivapharma.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r326" ] }, "iva_EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EntitySShareOfNetAssetsInInvestmentsAccountedForUsingEquityMethod", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Entity's share of net assets in investments accounted for using the equity method", "label": "Entity's share of net assets in investments accounted for using the equity method", "terseLabel": "Group's share" } } }, "auth_ref": [] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at the end", "periodStartLabel": "Balance at the beginning", "totalLabel": "Total Shareholders' equity", "verboseLabel": "Shareholders' equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r56", "r58", "r79", "r80", "r82", "r184", "r202", "r228", "r229", "r236", "r255", "r264" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and shareholders' equity", "verboseLabel": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r255" ] }, "iva_EquityOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EquityOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity offering.", "label": "Equity Offering [Member]", "verboseLabel": "Equity offering" } } }, "auth_ref": [] }, "iva_EquityOfferingPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EquityOfferingPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Price per ordinary share at which the entity's equity securities are offered and sold in an equity offering.", "label": "Equity Offering Price Per Share", "terseLabel": "Equity offering price" } } }, "auth_ref": [] }, "iva_EquityRecoveryLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EquityRecoveryLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for equity recovery loans.", "label": "Equity Recovery Loans [Member]", "terseLabel": "Equity recovery loans" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EuropeanInvestmentBankWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to European Investment Bank warrants.", "label": "European Investment Bank Warrants [Member]", "terseLabel": "EIB warrants" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EuropeanInvestmentBankWarrantsTrancheBMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for European Investment bank warrants Tranche B.", "label": "European Investment Bank Warrants Tranche B [Member]", "terseLabel": "EIB Warrants Tranche B" } } }, "auth_ref": [] }, "iva_EuropeanInvestmentBankWarrantsTrancheaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "EuropeanInvestmentBankWarrantsTrancheaMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for European Investment bank warrants Tranche A.", "label": "European Investment Bank Warrants Tranche A [Member]", "terseLabel": "EIB Warrants Tranche A" } } }, "auth_ref": [] }, "iva_ExpectedVolatility": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ExpectedVolatility", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expected volatility used to calculate fair value of stock and warrants.", "label": "Expected volatility", "verboseLabel": "Volatility" } } }, "auth_ref": [] }, "iva_ExpenseFromAcceleratedVestingOfShareBasedPaymentAwards": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ExpenseFromAcceleratedVestingOfShareBasedPaymentAwards", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from accelerated vesting of share-based payment awards", "label": "Expense from accelerated vesting of share-based payment awards", "negatedLabel": "Share-based compensation expense" } } }, "auth_ref": [] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions", "verboseLabel": "Share-based compensation expense" } } }, "auth_ref": [ "r108", "r210" ] }, "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Expense from share-based payment transactions with employees", "negatedLabel": "Sharebased compensation expense", "terseLabel": "Share-based compensation expense" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_ExpenseOfRestructuringActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ExpenseOfRestructuringActivities", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Expense of restructuring activities", "terseLabel": "Restructuring expenses" } } }, "auth_ref": [ "r276" ] }, "iva_ExpenseOfRestructuringActivitiesOtherThanExpensesRecordedAgainstOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ExpenseOfRestructuringActivitiesOtherThanExpensesRecordedAgainstOtherProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense of restructuring activities other than expenses recorded against other provisions.", "label": "Expense of restructuring activities other than expenses recorded against other provisions", "negatedLabel": "Restructuring expenses", "terseLabel": "Restructuring expenses" } } }, "auth_ref": [] }, "iva_ExpenseOfRestructuringActivitiesRecordedAgainstOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ExpenseOfRestructuringActivitiesRecordedAgainstOtherProvisions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense of restructuring activities recorded against other provisions.", "label": "Expense of restructuring activities recorded against other provisions", "negatedLabel": "Provisions - Restructuring", "terseLabel": "Provisions - Restructuring" } } }, "auth_ref": [] }, "iva_ExperienceInPharmaceuticalIndustry": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ExperienceInPharmaceuticalIndustry", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Experience in pharmaceutical industry.", "label": "Experience in pharmaceutical industry" } } }, "auth_ref": [] }, "iva_FairValueGainsOnConvertibleBonds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FairValueGainsOnConvertibleBonds", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value gains on convertible bonds.", "label": "Fair value gains on convertible bonds", "terseLabel": "Gains on fair value of Convertible option (Convertible Bonds)" } } }, "auth_ref": [] }, "iva_FairValueOfFinancialLiabilitiesRepurchasedAndCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FairValueOfFinancialLiabilitiesRepurchasedAndCancelled", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of fair value of financial liabilities repurchased and cancelled.", "label": "Fair Value of Financial Liabilities Repurchased and Cancelled", "terseLabel": "Amount of fair value of repurchase and cancelled" } } }, "auth_ref": [] }, "iva_FairValueOfForwardContractRecognisedInEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FairValueOfForwardContractRecognisedInEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of forward contract recognised in equity.", "label": "Fair value of forward contract recognised in equity" } } }, "auth_ref": [] }, "iva_FairValueOfWarrantsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FairValueOfWarrantsOutstanding", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrants outstanding", "label": "Fair value of warrants outstanding", "terseLabel": "Fair Value (k\u20ac)" } } }, "auth_ref": [] }, "iva_FairValueOfWarrantsToBeRepurchasedClassifiedAsDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FairValueOfWarrantsToBeRepurchasedClassifiedAsDerivatives", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of fair value of warrants to be repurchased classified as derivatives.", "label": "Fair Value Of Warrants To Be Repurchased Classified As Derivatives", "terseLabel": "Fair value" } } }, "auth_ref": [] }, "iva_Fees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Fees", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Fees expense.", "label": "Fees", "negatedLabel": "Fees" } } }, "auth_ref": [] }, "iva_FibroscanMachinesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FibroscanMachinesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for fibroscan machines.", "label": "Fibroscan machines", "terseLabel": "Fibroscan machines" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankFirstTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinanceContractWithEuropeanInvestmentBankFirstTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to first tranche of the finance contract with European Investment Bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, First Tranche [Member]", "terseLabel": "Finance contract with EIB, first tranche (Tranche A)", "verboseLabel": "EIB Tranche A 2022" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinanceContractWithEuropeanInvestmentBankMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the Finance contract with the European Investment Bank", "label": "Finance contract with European Investment Bank [Member]", "terseLabel": "Finance contract with EIB", "verboseLabel": "EIB loan" } } }, "auth_ref": [] }, "iva_FinanceContractWithEuropeanInvestmentBankSecondTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinanceContractWithEuropeanInvestmentBankSecondTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to second tranche of the finance contract with European investment bank (\"EIB\").", "label": "Finance Contract With European Investment Bank, Second Tranche [Member]", "terseLabel": "Finance contract with EIB, second tranche (Tranche B)", "verboseLabel": "EIB Tranche B 2024" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance costs", "negatedTerseLabel": "Financial expenses", "negatedTotalLabel": "Total financial expenses" } } }, "auth_ref": [ "r272" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Total financial income" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_FinanceIncomeCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinanceIncomeCost", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Net financial income", "totalLabel": "Financial income (loss)" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets", "terseLabel": "Financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r112", "r115", "r116", "r119", "r220", "r221", "r223", "r303" ] }, "ifrs-full_FinancialAssetsAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets at amortised cost, category [member]", "terseLabel": "Financial assets carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial assets at amortised cost category. [Refer: Financial assets at amortised cost]" } } }, "auth_ref": [ "r127", "r214" ] }, "ifrs-full_FinancialAssetsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialAssetsAtFairValue", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Financial assets, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } } }, "auth_ref": [ "r112" ] }, "iva_FinancialIncomeAndExpensesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancialIncomeAndExpensesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Financial Income And Expenses [Line Items]", "verboseLabel": "Financial income and expenses" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancialIncomeAndExpensesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information pertaining to disclosure of financial income and expenses.", "label": "Financial Income And Expenses [Table]" } } }, "auth_ref": [] }, "iva_FinancialIncomeAndExpensesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancialIncomeAndExpensesTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure of financial income and expense.", "label": "Financial Income and Expenses [Table Text Block]", "terseLabel": "Schedule of financial income and expenses" } } }, "auth_ref": [] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r112" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r128", "r215" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, category [member]", "verboseLabel": "Liabilities carried at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at amortised cost category. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r128", "r215" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCostMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at amortised cost, class [member]", "terseLabel": "Financial liabilities at amortized cost" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]" } } }, "auth_ref": [ "r130", "r148", "r217" ] }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities, at fair value", "verboseLabel": "Financial liabilities, at fair value" } }, "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } } }, "auth_ref": [ "r112" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss", "terseLabel": "Aggregate carrying amount" } }, "en": { "role": { "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r126", "r213" ] }, "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Financial liabilities at fair value through profit or loss, category [member]", "terseLabel": "Financial liabilities carried at fair value through profit or loss" } }, "en": { "role": { "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]" } } }, "auth_ref": [ "r126", "r213" ] }, "iva_FinancialLiabilitiesTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancialLiabilitiesTransactionCosts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transaction costs of financial liabilities.", "label": "Financial Liabilities, Transaction Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingArrangementInThreeTranches2024Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches.", "label": "Financing arrangement in three tranches 2024 [Member]", "terseLabel": "2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingArrangementInThreeTranches2024TrancheIMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche I.", "label": "Financing arrangement in three tranches 2024, Tranche I [Member]", "terseLabel": "Tranche I, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIiAndTrancheIiiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingArrangementInThreeTranches2024TrancheIiAndTrancheIiiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche II and Tranche III.", "label": "Financing arrangement in three tranches 2024, Tranche II and Tranche III [Member]", "terseLabel": "Tranche II and Tranche III, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingArrangementInThreeTranches2024TrancheIiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingArrangementInThreeTranches2024TrancheIiMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member represents the 2024 Financing arrangement in three tranches, Tranche II.", "label": "Financing arrangement in three tranches 2024, Tranche II [Member]", "terseLabel": "Tranche II, 2024 Financing arrangement in three tranches" } } }, "auth_ref": [] }, "iva_FinancingFromSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingFromSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for financing from a syndicate of French banks.", "label": "Financing from a syndicate of French banks", "terseLabel": "Financing from a syndicate of French banks" } } }, "auth_ref": [] }, "iva_FinancingPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "FinancingPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the financing period of loan.", "label": "Financing Period of Loan", "terseLabel": "Financing period of loan" } } }, "auth_ref": [] }, "ifrs-full_ForeignExchangeGain": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeGain", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange gain", "terseLabel": "Foreign exchange gains" } } }, "auth_ref": [ "r15", "r181", "r246" ] }, "ifrs-full_ForeignExchangeLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeLoss", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange loss", "negatedLabel": "Foreign exchange losses" } } }, "auth_ref": [ "r15", "r181", "r246" ] }, "ifrs-full_ForeignExchangeRatesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ForeignExchangeRatesAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceForeignExchangeRatesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange rates [abstract]", "terseLabel": "Foreign currency translation" } } }, "auth_ref": [] }, "iva_ForwardContractAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ForwardContractAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Forward contract at fair value.", "label": "Forward contract at fair value" } } }, "auth_ref": [] }, "iva_ForwardContractTransactionsCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ForwardContractTransactionsCosts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The transaction costs incurred in connection with the forward contract.", "label": "Forward Contract, Transactions Costs", "terseLabel": "Transaction costs" } } }, "auth_ref": [] }, "iva_GainLossOnExtinguishmentOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GainLossOnExtinguishmentOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on extinguishment of derivative liability.", "label": "Gain (Loss) On Extinguishment Of Derivative Liability", "terseLabel": "Extinguishment of the derivative financial liability" } } }, "auth_ref": [] }, "iva_GainLossOnInitialRecognitionOfForwardContractAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GainLossOnInitialRecognitionOfForwardContractAtFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Gain (loss) on initial recognition of forward contract at fair value.", "label": "Gain (loss) on initial recognition of forward contract at fair value" } } }, "auth_ref": [] }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Actuarial gains or losses recognized in other comprehensive income" } }, "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } } }, "auth_ref": [ "r12", "r180" ] }, "iva_GainsArisingFromDerecognitionOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GainsArisingFromDerecognitionOfDerivatives", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of gains recognised arising from the derecognition of derivatives.", "label": "Gains Arising From Derecognition Of Derivatives", "terseLabel": "Gains on derecognition of Legacy EIB Warrants" } } }, "auth_ref": [] }, "ifrs-full_GainsLossesArisingFromSettlementsDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsLossesArisingFromSettlementsDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Gains (losses) arising from settlements, defined benefit plans", "terseLabel": "Benefits for the period" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Gains on change in fair value of derivatives", "terseLabel": "Fair value gains on derivatives" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r356" ] }, "ifrs-full_GainsOnDisposalsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GainsOnDisposalsOfInvestments", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Gains on disposals of investments", "terseLabel": "Gain on disposals of assets" } }, "en": { "role": { "documentation": "The gain on the disposal of investments." } } }, "auth_ref": [ "r277" ] }, "iva_GainsOnRepurchaseAndCancellationOfWarrantsClassifiedAsDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GainsOnRepurchaseAndCancellationOfWarrantsClassifiedAsDerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized upon repurchase and cancellation of warrants classified as derivative financial liabilities.", "label": "Gains On Repurchase And Cancellation Of Warrants Classified As Derivative Financial Liabilities", "verboseLabel": "Repurchase and cancellation of Legacy EIB Warrants" } } }, "auth_ref": [] }, "iva_GainsOnRestructuringOfWarrantsClassifiedAsDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GainsOnRestructuringOfWarrantsClassifiedAsDerivativeFinancialLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of gains recognized upon restructuring of warrants that are classified as derivative financial liabilities.", "label": "Gains On Restructuring Of Warrants Classified As Derivative Financial Liabilities", "verboseLabel": "Gains recognized upon restructuring of warrants" } } }, "auth_ref": [] }, "ifrs-full_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r144", "r279", "r300", "r302", "r315" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r144", "r279", "r300", "r302", "r315" ] }, "iva_GoingConcernLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GoingConcernLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.", "label": "Going Concern [Line Items]", "terseLabel": "Going Concern" } } }, "auth_ref": [] }, "iva_GoingConcernTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "GoingConcernTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to going concern.", "label": "Going Concern [Table]" } } }, "auth_ref": [] }, "ifrs-full_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Goodwill", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill" } }, "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r28", "r30", "r109", "r186", "r188", "r211", "r247" ] }, "ifrs-full_GrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "GrossCarryingAmountMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross carrying amount [member]", "verboseLabel": "Gross" } } }, "auth_ref": [ "r7", "r35", "r40", "r43", "r109", "r116", "r119", "r176", "r193", "r198", "r201", "r221", "r223", "r303" ] }, "iva_HepalysPharmaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "HepalysPharmaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Hepalys Pharma, Inc.", "label": "Hepalys Pharma, Inc [Member]", "terseLabel": "Hepalys Pharma, Inc" } } }, "auth_ref": [] }, "iva_HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "HoldingPeriodOfAwardsGrantedInShareBasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the holding period of awards granted in share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Holding Period Of Awards Granted In Share-Based Payment Arrangement", "terseLabel": "Holding period (year)" } } }, "auth_ref": [] }, "iva_IfrsAccountsReceivableCreditLossExpenseReversal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsAccountsReceivableCreditLossExpenseReversal", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "IFRS Accounts Receivable, Credit Loss Expense (Reversal)", "negatedLabel": "Allowance for doubtful accounts" } } }, "auth_ref": [] }, "iva_IfrsAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsAllowanceForDoubtfulAccountsPremiumsAndOtherReceivables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "The valuation allowance as of the balance sheet date to reduce the gross amount of receivables to estimated net realizable value, which would be presented in parentheses on the face of the balance sheet.", "label": "IFRS Allowance for Doubtful Accounts, Premiums and Other Receivables", "negatedLabel": "Allowance for doubtful accounts" } } }, "auth_ref": [] }, "iva_IfrsBankOverdraftsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsBankOverdraftsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Bank Overdrafts [Member]", "label": "IFRS Bank Overdrafts [Member]", "terseLabel": "Bank overdraft" } } }, "auth_ref": [] }, "iva_IfrsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsCashAndCashEquivalentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for cash and cash equivalents.", "label": "Cash and Cash equivalents", "terseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Ifrs Class of Warrant or Right [Axis]" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Ifrs Class of Warrant or Right [Domain]" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrant", "verboseLabel": "Exercise price per warrant" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Ifrs Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of shares per warrant", "verboseLabel": "Number of shares per instrument" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "IFRS Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Number of shares callable by warrants" } } }, "auth_ref": [] }, "iva_IfrsClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "IFRS Class of Warrant or Right, Outstanding", "terseLabel": "Number of share warrants outstanding", "verboseLabel": "Number of warrants outstanding" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Company information", "terseLabel": "Revenues and other income", "verboseLabel": "Collaborative Arrangements" } } }, "auth_ref": [] }, "iva_IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsCollaborativeArrangementAndArrangementOtherThanCollaborativeTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "IFRS Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsDebtInstrumentConvertibleConversionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Ifrs Debt Instrument, Convertible, Conversion Price", "terseLabel": "Convertible, Conversion price" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentConvertibleConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsDebtInstrumentConvertibleConversionRatio", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Ifrs Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio" } } }, "auth_ref": [] }, "iva_IfrsDebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsDebtInstrumentTerm", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Ifrs Debt Instrument, Term", "verboseLabel": "Maturity term after the disbursement of the tranche" } } }, "auth_ref": [] }, "iva_IfrsGeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsGeneralAndAdministrativeExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for general and administrative expense member.", "label": "General and administrative expenses" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsIncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in employee related liabilities.", "label": "IFRS Increase (Decrease) In Employee Related Liabilities", "terseLabel": "Increase (Decrease) in employee related liabilities" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsIncreaseDecreaseInOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other current liabilities of the entity.", "label": "IFRS Increase (Decrease) In Other Current Liabilities", "terseLabel": "Decrease in other current liabilities" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInOtherNonCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsIncreaseDecreaseInOtherNonCurrentAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other non-current assets during the reporting period.", "label": "IFRS Increase (Decrease) in Other Non-current Assets", "terseLabel": "Other non-current assets increased" } } }, "auth_ref": [] }, "iva_IfrsIncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsIncreaseDecreaseInPrepaidExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "IFRS Increase (Decrease) in Prepaid Expense", "terseLabel": "Increase (decrease) in prepaid expenses" } } }, "auth_ref": [] }, "iva_IfrsOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation.", "label": "Ifrs Other Operating Income", "terseLabel": "Other" } } }, "auth_ref": [] }, "iva_IfrsPaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsPaymentsForRepurchaseOfWarrants", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.", "label": "IFRS Payments for Repurchase of Warrants", "negatedLabel": "Repurchase of prefunded Warrants" } } }, "auth_ref": [] }, "iva_IfrsProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "IFRS Proceeds from Issuance of Warrants", "terseLabel": "Issue of warrants" } } }, "auth_ref": [] }, "iva_IfrsResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for research and development expense member.", "label": "Ifrs Research And Development Expense [Member]", "verboseLabel": "Research and development expenses" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsSaleOfStockAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "IFRS Sale of Stock [Axis]" } } }, "auth_ref": [] }, "iva_IfrsSaleOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsSaleOfStockDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "IFRS Sale of Stock [Domain]" } } }, "auth_ref": [] }, "iva_IfrsSalesAndMarketingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsSalesAndMarketingExpenseMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for sales and marketing expense member.", "label": "Marketing - Business development expenses", "verboseLabel": "Marketing - business development expenses" } } }, "auth_ref": [] }, "iva_IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "Period which the right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "IFRS Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "verboseLabel": "Vesting period (year)" } } }, "auth_ref": [] }, "iva_IfrsSharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IfrsSharesIssuedPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Ifrs Shares Issued, Price Per Share", "terseLabel": "Price per share" } } }, "auth_ref": [] }, "iva_ImpliedStockOptionsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ImpliedStockOptionsFairValue", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "Implied stock options fair value", "label": "Implied stock options fair values" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax" } } }, "auth_ref": [ "r1", "r2", "r3", "r19", "r74", "r134", "r170", "r171", "r172", "r273" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Tax credit received" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r49", "r285" ] }, "iva_IncreaseDecreaseInAccruedSalariesAndOtherEmployeeRelatedTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInAccruedSalariesAndOtherEmployeeRelatedTaxes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued salaries and other employee related taxes.", "label": "Increase (Decrease) In Accrued Salaries And Other Employee Related Taxes", "terseLabel": "Accrued salaries and other employee related taxes" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r54", "r167" ] }, "iva_IncreaseDecreaseInCurrentValueAddedTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInCurrentValueAddedTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in current value added tax liabilities", "label": "Increase (decrease) in current value added tax liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in lease liabilities during the period.", "label": "Increase (Decrease) in Lease Liabilities", "terseLabel": "Increase (decrease) in lease liabilities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities other than through cash flow.", "label": "Increase (Decrease) In Liabilities Arising From Financing Activities Other Than Through Cash Flows", "totalLabel": "Non-cash from (used in) financing activities" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPrincipalReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesThroughPrincipalReceived", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in liabilities arising from financing activities through principal received.", "label": "Increase (decrease) in liabilities arising from financing activities through principal received", "terseLabel": "Principal received" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInLiabilitiesArisingFromInitialRecognitionAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInLiabilitiesArisingFromInitialRecognitionAtFairValue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in liabilities arising from initial recognition at fair value.", "label": "Increase (Decrease) In Liabilities Arising From Initial Recognition At Fair Value", "terseLabel": "Initital recognition at fair value" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from expense (income) in profit or loss", "negatedLabel": "Gain / (Expense) for the period" } } }, "auth_ref": [ "r331" ] }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "verboseLabel": "Number of shares" } }, "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } } }, "auth_ref": [ "r160", "r231", "r266" ] }, "iva_IncreaseDecreaseInOtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInOtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other accrued taxes and employee related expenses.", "label": "Increase (Decrease) In Other Accrued Taxes And Employee Related Expenses", "terseLabel": "Increase (Decrease) in other accrued taxes and employee related expenses" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInOtherMiscellaneousCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in other miscellaneous current liabilities of the entity.", "label": "Increase (Decrease) In Other Miscellaneous Current Liabilities", "terseLabel": "Decrease in other miscellaneous liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInPropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in property, plant and equipment including right-of-use assets", "negatedLabel": "Decrease in property, plant and equipment including right-of-use assets" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment including right-of-use assets. [Refer: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r329" ] }, "iva_IncreaseDecreaseInShortTermDepositAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInShortTermDepositAccounts", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in short-term deposit accounts.", "label": "Increase (Decrease) In Short-Term Deposit Accounts", "terseLabel": "Increase in short-term deposit accounts" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInTradeAccountsPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in trade accounts payable", "label": "Increase (decrease) in trade accounts payable", "terseLabel": "Decrease in trade accounts payable" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseInTradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseInTradeAndOtherCurrentReceivables", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in trade and other current receivables.", "label": "Increase (Decrease) in Trade and other current receivables", "terseLabel": "Increase (decrease) in trade and other current receivables." } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseInWorkingCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Tax and changes in operating working capital" } }, "en": { "role": { "documentation": "The increase (decrease) in working capital." } } }, "auth_ref": [ "r339" ] }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Appropriation of net income (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } } }, "auth_ref": [ "r347" ] }, "iva_IncreaseDecreaseThroughCapitalVariations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseThroughCapitalVariations", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through capital variations, equity", "label": "Increase (decrease) through capital variations", "terseLabel": "Capital variations" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughCatchUpImpactOfDebtRemeasurementLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseThroughCatchUpImpactOfDebtRemeasurementLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from through catch up impact of remeasurement.", "label": "Increase (Decrease) Through Catch Up Impact Of Debt Remeasurement Liabilities Arising From Financing Activities", "terseLabel": "Catch-up impact of the debt remeasurement" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughChangesInFairValuesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through changes in fair values, liabilities arising from financing activities", "terseLabel": "Change in fair value" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from changes in fair values. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r52", "r164" ] }, "iva_IncreaseDecreaseThroughCumulativeFixedInterestAccrualsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseThroughCumulativeFixedInterestAccrualsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through cumulative fixed interest accruals, liabilities arising from financing activities.", "label": "Increase (decrease) through cumulative fixed interest accruals, liabilities arising from financing activities", "terseLabel": "Cumulative fixed interest expense accrual" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through effect of changes in foreign exchange rates, liabilities arising from financing activities", "terseLabel": "Foreign exchange gain (loss)" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r51", "r163" ] }, "ifrs-full_IncreaseDecreaseThroughExerciseOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughExerciseOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through exercise of warrants, equity", "terseLabel": "Vesting of bonus shares", "verboseLabel": "Exercise of warrants" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the exercise of warrants." } } }, "auth_ref": [ "r347" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through financing cash flows, liabilities arising from financing activities", "terseLabel": "Cash flow from (used in) financing activities" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r50", "r162" ] }, "iva_IncreaseDecreaseThroughIssuanceOfWarrantsEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseThroughIssuanceOfWarrantsEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) in equity resulting from the issuance of warrants.", "label": "Increase Decrease Through Issuance Of Warrants, Equity", "terseLabel": "Issue of prefunded warrants" } } }, "auth_ref": [] }, "iva_IncreaseDecreaseThroughReassessmentsAndRemeasurementsLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseDecreaseThroughReassessmentsAndRemeasurementsLeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through reassessments and remeasurements, lease liabilities.", "label": "Increase (decrease) through reassessments and remeasurements, lease liabilities" } } }, "auth_ref": [] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based payment compensation expenses", "verboseLabel": "Capital increase arising from the vesting of bonus share awards" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r242" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "terseLabel": "Other" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } } }, "auth_ref": [ "r243" ] }, "iva_IncreaseInSharesThroughIssueOfOrdinaryShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IncreaseInSharesThroughIssueOfOrdinaryShares", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "The increase in shares resulting from the issuance of shares.", "label": "Increase In Shares Through Issue of Ordinary Shares", "terseLabel": "Issue of ordinary shares (in shares)" } } }, "auth_ref": [] }, "ifrs-full_IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IncreaseThroughNewLeasesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails": { "parentTag": "iva_IncreaseDecreaseInLiabilitiesArisingFromFinancingActivitiesOtherThanThroughCashFlows", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Increase through new leases, liabilities arising from financing activities", "terseLabel": "Lease new contract / reassessment" } }, "en": { "role": { "documentation": "The increase in liabilities arising from financing activities resulting from new leases. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r290", "r293" ] }, "ifrs-full_InsuranceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InsuranceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Insurance expense", "negatedLabel": "Insurance" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Intangible assets other than goodwill", "terseLabel": "Intangible assets" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r36", "r194", "r247" ] }, "iva_IntercompanyEliminationsInAssociates": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IntercompanyEliminationsInAssociates", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of intercompany eliminations in associates", "label": "Intercompany Eliminations in Associates", "negatedLabel": "Elimination of unrealized profit on downstream sales" } } }, "auth_ref": [] }, "ifrs-full_InterestCostsCapitalised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestCostsCapitalised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "label": "Interest costs capitalised", "terseLabel": "Capitalized interest" } }, "en": { "role": { "documentation": "The amount of interest costs that an entity incurs in connection with the borrowing of funds that are directly attributable to the acquisition, construction or production of a qualifying asset and which form part of the cost of that asset." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest cost" } }, "en": { "role": { "documentation": "The amount of expense arising from interest." } } }, "auth_ref": [ "r73", "r133", "r141" ] }, "ifrs-full_InterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense, defined benefit plans", "negatedLabel": "Interest cost for the period" } } }, "auth_ref": [ "r330" ] }, "ifrs-full_InterestIncomeOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnCashAndCashEquivalents", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on cash and cash equivalents", "terseLabel": "Income from cash equivalents" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_InterestIncomeOnDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestIncomeOnDeposits", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Interest income on deposits", "terseLabel": "Interest income on deposits" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "Interest paid" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r48" ] }, "ifrs-full_InterestPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InterestPayable", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Interest payable", "terseLabel": "Accrued interest payable on loans" } }, "en": { "role": { "documentation": "The amount of interest recognised as a liability." } } }, "auth_ref": [ "r349" ] }, "iva_InventivaIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "InventivaIncMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva Inc, U.S. affiliate.", "label": "Inventiva Inc [Member]", "terseLabel": "Inventiva Inc." } } }, "auth_ref": [] }, "iva_InventivaS.aMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "InventivaS.aMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Inventiva S.A, U.S. affiliate.", "label": "Inventiva S.A [Member]", "terseLabel": "Inventiva S.A" } } }, "auth_ref": [] }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "InvestmentAccountedForUsingEquityMethod", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Investments accounted for using equity method", "netLabel": "Carrying amount", "terseLabel": "Investments accounted for using the equity method" } }, "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } } }, "auth_ref": [ "r76", "r136", "r227", "r248" ] }, "iva_IssuanceOfWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "IssuanceOfWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for issuance of warrants", "label": "Issuance of warrants [Member]", "terseLabel": "Issuance of warrants" } } }, "auth_ref": [] }, "ifrs-full_IssueOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssueOfEquity", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Issue of ordinary shares", "verboseLabel": "Issue of equity" } }, "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } } }, "auth_ref": [ "r242" ] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r317", "r323" ] }, "ifrs-full_IssuedCapitalMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "IssuedCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } } }, "auth_ref": [ "r244" ] }, "iva_ItSystems": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ItSystems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "IT systems expense.", "label": "IT Systems", "negatedLabel": "IT systems" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Later than five years [member]", "terseLabel": "More than 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r90", "r91", "r95", "r153", "r156", "r306", "r310", "r313" ] }, "ifrs-full_LaterThanOneMonthAndNotLaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneMonthAndNotLaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Later than one month and not later than two months [member]", "terseLabel": "Due in 30-60 days" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one month and not later than two months." } } }, "auth_ref": [ "r303", "r312", "r349" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanThreeYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanThreeYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than three years [member]", "terseLabel": "Between 1 and 3 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than three years." } } }, "auth_ref": [ "r306", "r308", "r313" ] }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Later than three years and not later than five years [member]", "terseLabel": "Between 3 and 5 years" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than five years." } } }, "auth_ref": [ "r306", "r309", "r313" ] }, "iva_LaterThanTwoMonthsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LaterThanTwoMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a time band of later than two months.", "label": "Due in more than 60 days", "terseLabel": "Due in more than 60 days" } } }, "auth_ref": [] }, "iva_LeaseCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LeaseCommitmentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for lease commitments.", "label": "Lease commitments [Member]", "terseLabel": "Lease" } } }, "auth_ref": [] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r89" ] }, "ifrs-full_LeaseLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LeaseLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities [member]", "terseLabel": "Lease liabilities", "verboseLabel": "Lease" } }, "en": { "role": { "documentation": "This member stands for lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r291", "r294" ] }, "iva_LegacyEuropeanInvestmentBankWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LegacyEuropeanInvestmentBankWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Legacy European Investment Bank warrants.", "label": "Legacy European Investment Bank Warrants [Member]", "terseLabel": "Legacy EIB warrants" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LegalEntityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ifrs-full_LegalProceedingsProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LegalProceedingsProvision", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Legal proceedings provision" } }, "en": { "role": { "documentation": "The amount of provision for legal proceedings. [Refer: Other provisions]" } } }, "auth_ref": [ "r283", "r284" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r27", "r29", "r80", "r187", "r229" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r13", "r80", "r229" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [domain]" } }, "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r13", "r80", "r229" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r79", "r80", "r82", "r135", "r140", "r228", "r229", "r255" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r165", "r292" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r165", "r292" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [domain]" } }, "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r165", "r292" ] }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LiabilityAssetOfDefinedBenefitPlans", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInNetProvisionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionNetProvisionDetails" ], "lang": { "en-us": { "role": { "label": "Net defined benefit liability (asset)", "negatedPeriodEndLabel": "Provision at end of period", "negatedPeriodStartLabel": "Provision at beginning of period", "terseLabel": "Total obligation" } }, "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [domain]]" } } }, "auth_ref": [ "r11", "r179" ] }, "iva_LicenseAgreementIssueOfCreditNotes": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LicenseAgreementIssueOfCreditNotes", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement, issue of credit notes.", "label": "License agreement, issue of credit notes" } } }, "auth_ref": [] }, "iva_LicenseAgreementPayablesForCreditNotesToBeIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LicenseAgreementPayablesForCreditNotesToBeIssued", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "License agreement, payables for credit notes to be issued.", "label": "License agreement, payables for credit notes to be issued" } } }, "auth_ref": [] }, "iva_LicensingAndCollaborationAgreementWithCttqMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LicensingAndCollaborationAgreementWithCttqMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Licensing and collaboration agreement with CTTQ.", "label": "Licensing and collaboration agreement with CTTQ [Member]", "terseLabel": "Licensing and collaboration agreement with CTTQ" } } }, "auth_ref": [] }, "iva_LiquidityAgreementAnnualExtensionTermIfNotTerminated": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LiquidityAgreementAnnualExtensionTermIfNotTerminated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Liquidity agreement, annual extension term if not terminated", "label": "Liquidity agreement, annual extension term if not terminated" } } }, "auth_ref": [] }, "iva_LiquidityAgreementWithKeplerCheuvreuxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LiquidityAgreementWithKeplerCheuvreuxMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLiquidityAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents the Liquidity agreement with Kepler Cheuvreux.", "label": "Liquidity agreement with Kepler Cheuvreux [Member]", "terseLabel": "Liquidity agreement with Kepler Cheuvreux" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks.", "label": "Loan Agreements With Syndicate of French Banks [Member]", "verboseLabel": "Loan agreements with a syndicate of French banks" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)", "label": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat) [Member]", "terseLabel": "Loan agreements with syndicate of French banks, state guaranteed loan (Pret Garanti par l'Etat)" } } }, "auth_ref": [] }, "iva_LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for loan agreements with a syndicate of French banks, under a stimulus economic plan.", "label": "Loan agreements with syndicate of French banks, under stimulus economic plan [Member]", "terseLabel": "Loan agreements with syndicate of French banks, under stimulus economic plan" } } }, "auth_ref": [] }, "ifrs-full_LoansReceived": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LoansReceived", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Loans received", "verboseLabel": "Bank borrowings" } }, "en": { "role": { "documentation": "The amount of loans received." } } }, "auth_ref": [ "r349" ] }, "iva_LongTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LongTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for long term deposit accounts.", "label": "Long-term deposit accounts", "terseLabel": "Long-term deposit accounts" } } }, "auth_ref": [] }, "iva_LongTermFinancialDebtDerivativesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LongTermFinancialDebtDerivativesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesFairValueMeasurementDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Long-term financial debt, derivatives.", "label": "Long-term financial debt - derivatives [Member]", "terseLabel": "Long-term financial debt - derivatives", "verboseLabel": "Derivatives" } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term borrowings [member]", "terseLabel": "Long-term debt", "verboseLabel": "Long-term" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r291", "r294" ] }, "ifrs-full_LongtermDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LongtermDeposits", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "label": "Long-term deposits", "verboseLabel": "Long-term deposit accounts" } }, "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } } }, "auth_ref": [ "r352" ] }, "iva_LossOnInitialMeasurementAtFairValueOfCashCollateralDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LossOnInitialMeasurementAtFairValueOfCashCollateralDeposit", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of loss on initial measurement at fair value of cash collateral deposit.", "label": "Loss On Initial Measurement At Fair Value Of Cash Collateral Deposit", "negatedLabel": "Loss on initial measurement at fair value of the Lenders' Tranche B cash collateral deposit" } } }, "auth_ref": [] }, "iva_LossesArisingFromDerecognitionOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "LossesArisingFromDerecognitionOfDerivatives", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of losses recognised arising from the derecognition of derivatives.", "label": "Losses Arising From Derecognition Of Derivatives", "negatedLabel": "Loss on derecognition of emaining EIB warrant settlement obligation" } } }, "auth_ref": [] }, "ifrs-full_LossesOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "LossesOnChangeInFairValueOfDerivatives", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Losses on change in fair value of derivatives", "negatedTerseLabel": "Losses on fair value variation of Warrants", "terseLabel": "Losses on fair value variation" } }, "en": { "role": { "documentation": "The losses resulting from changes in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r356" ] }, "iva_MarkPruzanskiChairmanOfBoardOfDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MarkPruzanskiChairmanOfBoardOfDirectorsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Mark Pruzanski, Chairman of the Board of Directors.", "label": "Mark Pruzanski, Chairman of the Board of Directors [Member]", "terseLabel": "Mark Pruzanski, Chairman of the Board of Directors" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationTables" ], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Schedule of maturity analysis of financial liabilities" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r121", "r224" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r87", "r90", "r91", "r92", "r93", "r94", "r95", "r111", "r122", "r149", "r151", "r154", "r157", "r218", "r258", "r280", "r306" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Maturity [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r87", "r90", "r91", "r92", "r93", "r94", "r95", "r111", "r149", "r151", "r154", "r157", "r218", "r258", "r280", "r306", "r311" ] }, "iva_MaximumAdditionalUncommittedFinancingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MaximumAdditionalUncommittedFinancingAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum additional uncommitted financing available.", "label": "Maximum Additional Uncommitted Financing Amount", "terseLabel": "Additional uncommitted amount" } } }, "auth_ref": [] }, "iva_MaximumDebtToMarketCapitalizationRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MaximumDebtToMarketCapitalizationRatio", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum ratio of the entity's debt to its market capitalization permitted under the debt financing agreement.", "label": "Maximum Debt to Market Capitalization Ratio", "terseLabel": "Debt-to-market capitalization ratio" } } }, "auth_ref": [] }, "iva_MaximumUncommittedFinancingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MaximumUncommittedFinancingAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of maximum uncommitted financing available for potential drawdown by the entity.", "label": "Maximum Uncommitted Financing Amount", "terseLabel": "Maximum uncommitted financing amount" } } }, "auth_ref": [] }, "iva_MinimumEquityFinancingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MinimumEquityFinancingAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum amount of equity financing required to be completed as a condition to the closing of the financing transaction.", "label": "Minimum Equity Financing Amount", "terseLabel": "Minimum equity financing amount" } } }, "auth_ref": [] }, "iva_MinimumEquityFundraisingAmountToSatisfyDrawdownConditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MinimumEquityFundraisingAmountToSatisfyDrawdownConditions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum amount of equity fundraising to achieve satisfy the drawdown conditions.", "label": "Minimum Equity Fundraising Amount To Satisfy Drawdown Conditions", "terseLabel": "Minimum equity fundraising to satisfy the drawdown conditions" } } }, "auth_ref": [] }, "iva_MinimumExerciseAmountOfWarrantsToSatisfyDrawdownConditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MinimumExerciseAmountOfWarrantsToSatisfyDrawdownConditions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Minimum exercise amount of warrants to satisfy drawdown conditions.", "label": "Minimum exercise amount of warrants to satisfy drawdown conditions" } } }, "auth_ref": [] }, "iva_MinimumSpecifiedSecuredAccountsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "MinimumSpecifiedSecuredAccountsAmount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The minimum amount to be maintained in specified secured accounts, financial covenant.", "label": "Minimum Specified Secured Accounts Amount", "terseLabel": "Minimum amount to be maintained in specified secured accounts" } } }, "auth_ref": [] }, "ifrs-full_MiscellaneousOtherOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating expense", "negatedTotalLabel": "Total other operating expenses" } } }, "auth_ref": [ "r349" ] }, "ifrs-full_MiscellaneousOtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "MiscellaneousOtherOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_OtherOperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Miscellaneous other operating income", "totalLabel": "Total other operating income" } } }, "auth_ref": [ "r349" ] }, "iva_NetProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NetProceedsFromIssuingShares", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of net proceeds from issuing shares", "label": "Net Proceeds From Issuing Shares", "terseLabel": "Net proceeds from issuing shares" } } }, "auth_ref": [] }, "iva_NewBsa2021ShareWarrantPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NewBsa2021ShareWarrantPlanMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new BSA 2021 share warrant plan.", "label": "BSA 2021" } } }, "auth_ref": [] }, "iva_NewEuropeanInvestmentBankWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NewEuropeanInvestmentBankWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new European investment bank warrants.", "label": "New European Investment Bank Warrants [Member]", "terseLabel": "New European Investment Bank Warrants", "verboseLabel": "New EIB Warrants" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019BisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NewShareWarrantPlansBsa2019BisMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 bis).", "label": "BSA 2019 bis" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NewShareWarrantPlansBsa2019Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for new share warrant plans (\"BSA 2019\").", "label": "BSA 2019" } } }, "auth_ref": [] }, "iva_NewShareWarrantPlansBsa2019TerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NewShareWarrantPlansBsa2019TerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for a new share warrant plan (\"BSA 2019 ter).", "label": "BSA 2019 ter" } } }, "auth_ref": [] }, "iva_NonCurrentAdvancesToSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NonCurrentAdvancesToSuppliers", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails": { "parentTag": "ifrs-full_OtherNoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount represents the non current advances of suppliers.", "label": "Non Current Advances To Suppliers", "verboseLabel": "Advance payments - non-current" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NonCurrentPortionOfNonCurrentBorrowingsAndNonCurrentLeaseLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "Non-current portion of non-current borrowings and non-current lease liabilities", "label": "Non-current portion of non-current borrowings and non-current lease liabilities", "terseLabel": "Long-term debt" } } }, "auth_ref": [] }, "iva_NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NonCurrentPortionOfNonCurrentRoyaltyCertificatesIssued", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails": { "parentTag": "iva_DebtFinancial", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "The non-current portion of non-current royalty certificates issued.", "label": "Non-current Portion of Non-current Royalty Certificates Issued", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r0", "r169" ] }, "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NonadjustingEventsAfterReportingPeriodDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Non-adjusting events after reporting period [domain]" } }, "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } } }, "auth_ref": [ "r0", "r169" ] }, "ifrs-full_NoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interest" } }, "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r60", "r61", "r254" ] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total non-current assets", "verboseLabel": "Non-current assets" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r66", "r259", "r295" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentContractLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current contract liabilities", "terseLabel": "Long-term contract liabilities" } }, "en": { "role": { "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_NoncurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current derivative financial liabilities", "terseLabel": "Long-term debt - derivatives", "verboseLabel": "Derivatives instruments" } }, "en": { "role": { "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total non-current liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r68", "r260", "r295" ] }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NoncurrentProvisionsForEmployeeBenefits", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Provisions for retirement benefit obligations" } }, "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } } }, "auth_ref": [ "r235", "r263" ] }, "ifrs-full_NotLaterThanOneMonthMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneMonthMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one month [member]", "terseLabel": "Due in 30 days" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one month." } } }, "auth_ref": [ "r305", "r307", "r313" ] }, "ifrs-full_NotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanOneYearMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Less than 1 year" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } } }, "auth_ref": [ "r90", "r91", "r95", "r152", "r155", "r257", "r306", "r313" ] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Not later than three months [member]", "terseLabel": "3 months or less" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r349" ] }, "iva_NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NotesToInterimCondensedConsolidatedStatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the unaudited interim condensed consolidated statement of financial position" } } }, "auth_ref": [] }, "iva_NotesToInterimCondensedConsolidatedStatementOfIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NotesToInterimCondensedConsolidatedStatementOfIncomeLossAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Notes to the interim condensed consolidated statement of income (loss)" } } }, "auth_ref": [] }, "ifrs-full_NotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NotionalAmount", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Notional amount", "terseLabel": "Notional amount", "verboseLabel": "Total amount of loan" } }, "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } } }, "auth_ref": [ "r349" ] }, "iva_NotionalAmountPerTranche": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NotionalAmountPerTranche", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Notional amount per tranche", "label": "Notional Amount Per Tranche", "terseLabel": "Notional amount per tranche" } } }, "auth_ref": [] }, "ifrs-full_NumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfEmployees", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Number of employees", "verboseLabel": "Number of employees" } }, "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } } }, "auth_ref": [ "r349" ] }, "iva_NumberOfEntitiesBeingConsolidated": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfEntitiesBeingConsolidated", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of entities being consolidated", "label": "Number of entities being consolidated", "terseLabel": "Number of entities being consolidated" } } }, "auth_ref": [] }, "iva_NumberOfEqualTranches": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfEqualTranches", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Represent the information of number of equal tranches .", "label": "Number of Equal Tranches", "terseLabel": "Number of equal tranches" } } }, "auth_ref": [] }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Issued", "verboseLabel": "Number of equity instruments granted" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } } }, "auth_ref": [ "r107", "r343" ] }, "iva_NumberOfLoanAgreements": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfLoanAgreements", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of loan agreements.", "label": "Number of Loan Agreements", "terseLabel": "Number of loan agreements" } } }, "auth_ref": [] }, "iva_NumberOfLoansObtainedGuaranteedByFrenchState": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfLoansObtainedGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of loans obtained which are guaranteed by the french state.", "label": "Number Of Loans Obtained Guaranteed By The French State", "verboseLabel": "Number of loans obtained guaranteed by the french state" } } }, "auth_ref": [] }, "iva_NumberOfMonthlyInstalments": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfMonthlyInstalments", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of monthly instalments", "label": "Number Of Monthly Instalments", "terseLabel": "Monthly instalments" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of exercisable shares" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r343" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "negatedLabel": "Forfeited / Lapsed" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r343" ] }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } }, "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r343" ] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of period" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r97", "r100", "r103", "r204", "r207" ] }, "iva_NumberOfPlansOutstanding": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfPlansOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of plans outstanding", "label": "Number of plans outstanding", "terseLabel": "Number of award plans outstanding" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "negatedLabel": "Forfeited/Lapsed" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r99", "r206" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Number of share options granted in share-based payment arrangement", "verboseLabel": "Issued" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r98", "r205" ] }, "iva_NumberOfSharesAcquiredInAssociate": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfSharesAcquiredInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired in associate", "label": "Number of shares acquired in associate", "terseLabel": "Number of shares acquired in associate" } } }, "auth_ref": [] }, "iva_NumberOfSharesCallablePerOption": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfSharesCallablePerOption", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares callable per option", "label": "Number of shares callable per option", "verboseLabel": "Number of shares per SO" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesOutstanding", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at the end (in shares)", "periodStartLabel": "Balance at the beginning (in shares)", "terseLabel": "Number of shares outstanding", "verboseLabel": "Number of fully authorized, subscribed and paid up shares" } }, "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } } }, "auth_ref": [ "r160", "r231", "r266" ] }, "iva_NumberOfSharesPerOtherEquityInstrumentGranted": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfSharesPerOtherEquityInstrumentGranted", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that each equity instruments other than share options granted in a share-based payment arrangement, entitles the holder.", "label": "Number Of Shares Per Other Equity Instrument Granted", "terseLabel": "Number of shares per AGA" } } }, "auth_ref": [] }, "ifrs-full_NumberOfSharesRepresentedByOneDepositaryReceipt": { "xbrltype": "pureItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "NumberOfSharesRepresentedByOneDepositaryReceipt", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails" ], "lang": { "en-us": { "role": { "label": "Number of shares represented by one depositary receipt", "terseLabel": "Number of ordinary shares represented by each ADS" } }, "en": { "role": { "documentation": "The number of shares represented by one depositary receipt." } } }, "auth_ref": [ "r349" ] }, "iva_NumberOfTradingDaysForVolumeWeightedAveragePrice": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfTradingDaysForVolumeWeightedAveragePrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of trading days used in the calculation of the volume-weighted average price of the entity's ordinary shares.", "label": "Number Of Trading Days For Volume Weighted Average Price", "terseLabel": "Trading days" } } }, "auth_ref": [] }, "iva_NumberOfTranchesDrawnDown": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfTranchesDrawnDown", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of tranches drawn down.", "label": "Number of tranches drawn down" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsApprovedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfWarrantsApprovedForIssuance", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants approved for issuance.", "label": "Number of warrants approved for issuance" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued", "label": "Number of warrants issued", "terseLabel": "Number of warrants issued" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsRepurchasedAndCancelled": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfWarrantsRepurchasedAndCancelled", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants repurchased and cancelled.", "label": "Number of Warrants Repurchased and Cancelled", "terseLabel": "Warrants repurchased and cancelled" } } }, "auth_ref": [] }, "iva_NumberOfWarrantsRepurchasedCancelledAndReplaced": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "NumberOfWarrantsRepurchasedCancelledAndReplaced", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants repurchased, cancelled and replaced by new warrants.", "label": "Number of Warrants Repurchased, Cancelled And Replaced", "terseLabel": "Remaining EIB warrants" } } }, "auth_ref": [] }, "iva_OpeningOfShortTermDepositAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OpeningOfShortTermDepositAccount", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "Opening of short-term deposit account.", "label": "Opening of short-term deposit account" } } }, "auth_ref": [] }, "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OperatingExpenseExcludingOtherOperatingIncomeExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Operating expense excluding other operating income (expense)", "label": "Operating Expense Excluding Other Operating Income Expense", "negatedTotalLabel": "Total operating expenses" } } }, "auth_ref": [] }, "iva_OptionToAcquireSharesInCompanyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OptionToAcquireSharesInCompanyPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Option to acquire shares in company, percentage", "label": "Option to acquire shares in company, percentage", "verboseLabel": "Option to acquire shares in company, percentage" } } }, "auth_ref": [] }, "iva_OtherAccruedTaxesAndEmployeeRelatedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherAccruedTaxesAndEmployeeRelatedExpenses", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of accrued taxes and employee related expenses.", "label": "Other Accrued taxes And Employee Related Expenses", "terseLabel": "Other accrued taxes and employee-related expenses" } } }, "auth_ref": [] }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherAdjustmentsForNoncashItems", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "Other" } } }, "auth_ref": [ "r338" ] }, "iva_OtherAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherAgreementsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other agreements.", "label": "Other Agreements [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "iva_OtherCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherCommitmentsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other commitments.", "label": "Other commitments [Member]", "terseLabel": "Others" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income", "totalLabel": "Total other comprehensive loss" } } }, "auth_ref": [ "r71", "r241", "r269", "r275" ] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Currency translation differences", "verboseLabel": "Exchange difference on translation of foreign operations" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r261", "r275" ] }, "iva_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationOfForeignOperationsIncludingEffectsOfTranslationOfInvestmentsAccountedForUsingEquityMethod", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations including effects of translation of investments accounted for using equity method", "terseLabel": "Currency translation differences" } } }, "auth_ref": [] }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Remeasurement of defined benefit plans" } }, "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [domain]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } } }, "auth_ref": [ "r261", "r275", "r330" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "Items that will be reclassified subsequently to profit or loss", "verboseLabel": "Items that will be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r324", "r325" ] }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "Items that will not be reclassified subsequently to profit or loss" } }, "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r324", "r325" ] }, "ifrs-full_OtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "iva_OtherCurrentAssetsAndTaxReceivables", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets", "totalLabel": "Other current assets" } }, "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } } }, "auth_ref": [ "r352" ] }, "iva_OtherCurrentAssetsAndTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherCurrentAssetsAndTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Other current assets and tax receivables.", "label": "Other current assets and tax receivables", "totalLabel": "Other current assets and tax receivables" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current liabilities", "totalLabel": "Other current liabilities" } }, "en": { "role": { "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails": { "parentTag": "ifrs-full_OtherCurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherCurrentAndNonCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other miscellaneous payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r352" ] }, "ifrs-full_OtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other receivables" } }, "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r316", "r322" ] }, "iva_OtherCurrentTaxReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherCurrentTaxReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_CurrentTaxAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of other tax receivables, classified as current.", "label": "Other Current Tax Receivables", "terseLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherFinanceCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherFinanceCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other financial expenses" } } }, "auth_ref": [ "r349" ] }, "iva_OtherFinancialInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherFinancialInformationAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Other financial information" } } }, "auth_ref": [] }, "iva_OtherIncomeFromOrdinaryActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherIncomeFromOrdinaryActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The amount of other income from ordinary activities.", "label": "Other income from ordinary activities", "terseLabel": "Other income", "totalLabel": "Total other income" } } }, "auth_ref": [] }, "ifrs-full_OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherInflowsOutflowsOfCashClassifiedAsOperatingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Other inflows (outflows) of cash, classified as operating activities", "verboseLabel": "Other" } }, "en": { "role": { "documentation": "Inflows (outflows) of cash, classified as operating activities, that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r45" ] }, "iva_OtherMiscellaneousPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherMiscellaneousPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other miscellaneous payables.", "label": "Other miscellaneous payables", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherNonCurrentAssetsLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Other Non Current Assets [Line Items]", "verboseLabel": "Other non-current assets" } } }, "auth_ref": [] }, "iva_OtherNonCurrentAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherNonCurrentAssetsTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to other non-current assets.", "label": "Other Non Current Assets [Table]" } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 4.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdvancesPaymentsNonCurrentDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current assets", "terseLabel": "Other non-current assets", "totalLabel": "Other non-current assets" } }, "en": { "role": { "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_OtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other non-current liabilities", "terseLabel": "Other non-current liabilities" } }, "en": { "role": { "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]" } } }, "auth_ref": [ "r352" ] }, "iva_OtherOperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherOperatingExpenses", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Other operating expenses.", "label": "Other operating expenses", "negatedLabel": "Other" } } }, "auth_ref": [] }, "ifrs-full_OtherOperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherOperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 5.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expenses)", "totalLabel": "Other operating income (loss)" } } }, "auth_ref": [ "r356" ] }, "iva_OtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherPayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents other payables.", "label": "Other payables [Member]", "terseLabel": "Other miscellaneous payables" } } }, "auth_ref": [] }, "ifrs-full_OtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisions", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions", "periodEndLabel": "Other provisions at end of period", "periodStartLabel": "Other provisions at beginning of period" } }, "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r31", "r189", "r235", "r263" ] }, "ifrs-full_OtherProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Other provisions [abstract]" } } }, "auth_ref": [] }, "iva_OtherReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for other receivables.", "label": "Other receivables", "terseLabel": "Other receivables" } } }, "auth_ref": [] }, "iva_OtherShortTermProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "OtherShortTermProvisionsAbstract", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Short term provisions" } } }, "auth_ref": [] }, "ifrs-full_OtherShorttermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "OtherShorttermProvisions", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Other current provisions", "periodEndLabel": "Closing balance", "periodStartLabel": "Beginning balance", "terseLabel": "Short-term provisions" } }, "en": { "role": { "documentation": "The amount of current provisions other than provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r235", "r263" ] }, "iva_PamelaHerbsterChiefPeopleOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PamelaHerbsterChiefPeopleOfficerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Pamela Herbster, Chief People Officer.", "label": "Pamela Herbster, Chief People Officer [Member]", "terseLabel": "Pamela Herbster, Chief People Officer" } } }, "auth_ref": [] }, "iva_ParValuePerBond": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ParValuePerBond", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "The nominal value per bond.", "label": "Par Value Per Bond", "terseLabel": "Par value per bond" } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails" ], "lang": { "en-us": { "role": { "label": "Par value per share", "verboseLabel": "Nominal value" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r159", "r230", "r265" ] }, "ifrs-full_PastServiceCostDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PastServiceCostDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Past service cost, defined benefit plans", "negatedLabel": "Past service costs" } } }, "auth_ref": [ "r330" ] }, "iva_PastServiceCostsAndInterestExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PastServiceCostsAndInterestExpenseDefinedBenefitPlans", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense and expense (income) resulting from past service cost arising from defined benefit plans.", "label": "Past Service Costs And Interest Expense, Defined Benefit Plans", "terseLabel": "Past service costs and interest expense defined benefit plans" } } }, "auth_ref": [] }, "iva_Patents": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Patents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Patents expense.", "label": "Patents", "negatedLabel": "Patents" } } }, "auth_ref": [] }, "iva_PayablesToSocialSecurityAndEmployeeBenefitOrganizationsRelatingToEmployerContributionsToShareBasedPaymentPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PayablesToSocialSecurityAndEmployeeBenefitOrganizationsRelatingToEmployerContributionsToShareBasedPaymentPlans", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Payables to social security and employee-benefit organizations relating to employer contributions to share-based payment plans.", "label": "Payables to social security and employee-benefit organizations relating to employer contributions to share-based payment plans" } } }, "auth_ref": [] }, "iva_PaymentOfAdvanceRelatedToBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PaymentOfAdvanceRelatedToBorrowings", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlowsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow associated with the advance payment related to borrowings.", "label": "Payment of Advance Related to Borrowings", "terseLabel": "Advance payment related to Lenders' Tranche B under Debt Financing agreement" } } }, "auth_ref": [] }, "ifrs-full_PaymentsForDebtIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForDebtIssueCosts", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Payments for debt issue costs", "terseLabel": "Payments for debt issue costs" } }, "en": { "role": { "documentation": "The cash outflow for debt issue costs." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_PaymentsForShareIssueCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsForShareIssueCosts", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for share issue costs", "negatedTerseLabel": "Transaction costs related to capital increase", "terseLabel": "Transaction costs related to capital increase" } }, "en": { "role": { "documentation": "The cash outflow for share issue costs." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "Repayment of lease liabilities", "terseLabel": "Repayment of lease liabilities" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r289" ] }, "iva_PenaltiesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PenaltiesExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of estimated penalties recognized in the period.", "label": "Penalties Expense", "negatedLabel": "Penalties" } } }, "auth_ref": [] }, "iva_PercentageOfLoanGuaranteedByFrenchState": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PercentageOfLoanGuaranteedByFrenchState", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of loan guaranteed by French state.", "label": "Percentage of Loan Guaranteed by French State", "terseLabel": "Percentage of loan guaranteed by French state" } } }, "auth_ref": [] }, "iva_PgeLoansAndPprLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PgeLoansAndPprLoansMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for PGE (Prt Garanti par l'Etat) loans and PPR (Prts Participatifs Relance) loans.", "label": "Pge Loans And Ppr Loans [Member]", "terseLabel": "PGE & PPR Loans" } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedBenefitPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedBenefitPlans", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionBreakdownOfExpenseRecognizedForPeriodDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss, defined benefit plans", "negatedTotalLabel": "Total" } } }, "auth_ref": [ "r330", "r332" ] }, "ifrs-full_PostemploymentBenefitExpenseInProfitOrLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseInProfitOrLoss", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Post-employment benefit expense in profit or loss", "negatedLabel": "Provisions for retirement benefit obligations" } } }, "auth_ref": [ "r332" ] }, "iva_PotentialProceedsFromDebtFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PotentialProceedsFromDebtFinancing", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails" ], "lang": { "en-us": { "role": { "documentation": "Potential gross proceeds that may be received by the entity upon the issuance of debt financing.", "label": "Potential Proceeds from Debt Financing", "terseLabel": "Potential gross proceeds" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "Subscription of borrowings", "verboseLabel": "Loan obtained" } }, "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } } }, "auth_ref": [ "r287" ] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of warrants", "terseLabel": "Proceeds from exercise of warrants" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r337" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Capital increase", "verboseLabel": "Proceeds from issuance of shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r286" ] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0, "order": 2.0 }, "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "Net loss for the period", "totalLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r57", "r59", "r135", "r138", "r185", "r203", "r240", "r268", "r295", "r301" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating profit (loss)", "verboseLabel": "Net operating loss" } } }, "auth_ref": [ "r281", "r356" ] }, "ifrs-full_PropertyPlantAndEquipmentIncludingRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "PropertyPlantAndEquipmentIncludingRightofuseAssets", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionIntangibleAssetsAndPropertyPlantAndEquipmentDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment including right-of-use assets", "terseLabel": "Property, plant and equipment" } }, "en": { "role": { "documentation": "The amount of property, plant and equipment including right-of-use assets whose underlying assets would be presented as property, plant and equipment if they were owned. [Refer: Property, plant and equipment; Right-of-use assets]" } } }, "auth_ref": [ "r88", "r329", "r351" ] }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInAssociate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Group's share in %", "verboseLabel": "Proportion of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]" } } }, "auth_ref": [ "r20", "r22", "r64" ] }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProportionOfOwnershipInterestInSubsidiary", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Proportion of ownership interest in subsidiary", "terseLabel": "Percent of ownership interest" } }, "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r20", "r22", "r62" ] }, "ifrs-full_ProvisionUsedOtherProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ProvisionUsedOtherProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Provision used, other provisions", "negatedLabel": "Reversals used" } }, "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } } }, "auth_ref": [ "r33", "r191" ] }, "iva_ProvisionUsedOtherShortTermProvisions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ProvisionUsedOtherShortTermProvisions", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other short-term provisions.", "label": "Provision used, other short-term provisions", "negatedLabel": "Reversals used" } } }, "auth_ref": [] }, "iva_ProvisionsLitigations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ProvisionsLitigations", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails": { "parentTag": "ifrs-full_MiscellaneousOtherOperatingExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOtherOperatingIncomeAndExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for litigations.", "label": "Provisions Litigations", "negatedLabel": "Provisions - Litigations" } } }, "auth_ref": [] }, "iva_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethodPricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Purchase of interests in investments accounted for using equity method, price per share", "label": "Purchase of interests in investments accounted for using equity method, price per share", "terseLabel": "Purchase of interests in investments accounted for using equity method, price per share" } } }, "auth_ref": [] }, "iva_PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "PurchaseOfPropertyPlantAndEquipmentAndIntangibleAssetsClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "label": "Purchase Of Property Plant And Equipment And Intangible Assets Classified As Investing Activities", "negatedLabel": "Purchases of property, plant and equipment and intangible assets" } } }, "auth_ref": [] }, "ifrs-full_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Range [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53", "r83", "r94", "r103", "r166", "r297", "r299", "r344" ] }, "ifrs-full_RangeDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RangeDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Range [domain]" } }, "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "auth_ref": [ "r53", "r83", "r94", "r103", "r166", "r297", "r299", "r344" ] }, "iva_RegisteredUnderwrittenPublicOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RegisteredUnderwrittenPublicOfferingMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for registered underwritten public offering.", "label": "Registered Underwritten Public Offering [Member]", "terseLabel": "Registered underwritten public offering" } } }, "auth_ref": [] }, "ifrs-full_RelatedPartiesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RelatedPartiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Total for all related parties [member]", "terseLabel": "Related parties" } }, "en": { "role": { "documentation": "This member stands for related parties. Related parties are persons or entities that are related to the entity that is preparing its financial statements (the reporting entity). (a) A person or a close member of that person\u2019s family is related to a reporting entity if that person: (i) has control or joint control over the reporting entity; (ii) has significant influence over the reporting entity; or (iii) is a member of the key management personnel of the reporting entity or of a parent of the reporting entity. (b) An entity is related to a reporting entity if any of the following conditions applies: (i) The entity and the reporting entity are members of the same group (which means that each parent, subsidiary and fellow subsidiary is related to the others). (ii) One entity is an associate or joint venture of the other entity (or an associate or joint venture of a member of a group of which the other entity is a member). (iii) Both entities are joint ventures of the same third party. (iv) One entity is a joint venture of a third entity and the other entity is an associate of the third entity. (v) The entity is a post-employment benefit plan for the benefit of employees of either the reporting entity or an entity related to the reporting entity. If the reporting entity is itself such a plan, the sponsoring employers are also related to the reporting entity. (vi) The entity is controlled or jointly controlled by a person identified in (a). (vii) A person identified in (a)(i) has significant influence over the entity or is a member of the key management personnel of the entity (or of a parent of the entity). (viii) The entity, or any member of a group of which it is a part, provides key management personnel services to the reporting entity or to the parent of the reporting entity. [Refer: Total for all joint ventures [member]; Key management personnel of entity or parent [member]]" } } }, "auth_ref": [ "r18", "r183" ] }, "ifrs-full_RepairsAndMaintenanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepairsAndMaintenanceExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Repairs and maintenance expense", "negatedLabel": "Maintenance" } } }, "auth_ref": [ "r356" ] }, "iva_RepaymentPeriodOfLoan": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RepaymentPeriodOfLoan", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for repayment of loan.", "label": "Repayment Period of Loan", "terseLabel": "Repayment period for loan" } } }, "auth_ref": [] }, "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFrenchStateGuaranteedLoanpgeAndEquityRecoveryLoanspprDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of borrowings, classified as financing activities", "negatedLabel": "Repayment of debt", "terseLabel": "Repayments of borrowings" } }, "en": { "role": { "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]" } } }, "auth_ref": [ "r288" ] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development costs" } } }, "auth_ref": [ "r38", "r196" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslation", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Translation reserve" } }, "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r16", "r182" ] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Translation Reserves" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r16", "r182", "r320" ] }, "ifrs-full_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "label": "Restricted cash and cash equivalents", "terseLabel": "Minimum cash covenant under Debt Financing Transaction" } }, "en": { "role": { "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_RestructuringProvision": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RestructuringProvision", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring provision", "terseLabel": "Expenses recorded on short-term provisions", "verboseLabel": "Restructuring and restructuring-related provisions" } }, "en": { "role": { "documentation": "The amount of provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions]" } } }, "auth_ref": [ "r282" ] }, "iva_RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodAndTreasuryShares", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "documentation": "A component of equity representing retained earnings excluding profit (loss) for the reporting period, and treasury shares", "label": "Retained earnings excluding profit (loss) for the reporting period and treasury shares", "terseLabel": "Reserves" } } }, "auth_ref": [] }, "iva_RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "This member represent a component of equity consisting of retained earnings excluding the current reporting period, and treasury shares.", "label": "Retained earnings excluding profit (loss) from current reporting period and treasury shares [Member]", "terseLabel": "Reserves (Accumulated losses)" } } }, "auth_ref": [] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net loss for the period" } }, "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } } }, "auth_ref": [ "r354" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r348" ] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "totalLabel": "Total revenues" } } }, "auth_ref": [ "r70", "r110", "r132", "r137", "r142", "r143", "r145", "r271", "r295", "r318", "r319" ] }, "ifrs-full_RevenueAndOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueAndOperatingIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue and other operating income", "totalLabel": "Total revenues and other income" } } }, "auth_ref": [ "r356" ] }, "iva_RevenueAndOtherIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RevenueAndOtherIncomeTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue and other income.", "label": "Revenue and Other Income [Table Text Block]", "terseLabel": "Schedule of revenues and other income" } } }, "auth_ref": [] }, "ifrs-full_RevenueFromContractsWithCustomers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "RevenueFromContractsWithCustomers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_RevenueAndOperatingIncome", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "ifrs-full_Revenue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue", "verboseLabel": "Revenues" } } }, "auth_ref": [ "r85", "r86", "r150" ] }, "iva_RoyaltyCertificateLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificateLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Royalty Certificate Liabilities.", "label": "Royalty Certificate Liabilities [Member]", "terseLabel": "Royalty Certificate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificates2023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificates2023Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to royalty certificates 2023.", "label": "Royalty Certificates 2023 [Member]", "terseLabel": "2023 Royalty Certificates" } } }, "auth_ref": [] }, "iva_RoyaltyCertificates2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificates2024Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates 2024.", "label": "Royalty Certificates 2024 [Member]", "terseLabel": "2024 Royalty Certificates" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesEffectiveInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificatesEffectiveInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Effective interest rate on royalty certificates.", "label": "Royalty Certificates, Effective Interest Rate", "terseLabel": "Royalty certificates, effective interest rate" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificatesLiabilitiesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for royalty certificates liabilities.", "label": "Royalty Certificates Liabilities [Member]", "terseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "iva_RoyaltyCertificatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "RoyaltyCertificatesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The information pertaining to royalty certificates.", "label": "Royalty Certificates [Member]", "verboseLabel": "Royalty certificates liabilities" } } }, "auth_ref": [] }, "ifrs-full_SalesAndMarketingExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SalesAndMarketingExpense", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing - Business development expenses" } } }, "auth_ref": [ "r356" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioForecastMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [] }, "iva_ScheduleOfValuationApproachForEuropeanInvestmentBankWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ScheduleOfValuationApproachForEuropeanInvestmentBankWarrantsTableTextBlock", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value of European Investment Bank Warrants.", "label": "Schedule Of Valuation Approach For European Investment Bank Warrants [Table Text Block]", "terseLabel": "Schedule of valuation approach for European investment bank warrants" } } }, "auth_ref": [] }, "iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Senior secured debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital.", "label": "Senior secured debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital [member]", "terseLabel": "Lenders' senior secured debt" } } }, "auth_ref": [] }, "iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheAndBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheAndBMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Senior secured debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A and B.", "label": "Senior secured debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A and B [member]", "terseLabel": "Lenders' Tranche A and B", "verboseLabel": "BlackRock - Claret Tranche A & B" } } }, "auth_ref": [] }, "iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheBMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Senior secured debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche B.", "label": "Senior secured debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche B [member]", "terseLabel": "Lenders' Tranche B" } } }, "auth_ref": [] }, "iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheCMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Senior secured debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche C.", "label": "Senior secured debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche C [member]", "terseLabel": "Lenders' Tranche C" } } }, "auth_ref": [] }, "iva_SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SeniorSecuredDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Senior secured debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A.", "label": "Senior secured debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A [member]", "terseLabel": "Lenders' Tranche A" } } }, "auth_ref": [] }, "ifrs-full_ShareIssueRelatedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareIssueRelatedCost", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Share issue related cost", "negatedTerseLabel": "Transaction costs", "verboseLabel": "Transaction costs" } } }, "auth_ref": [ "r347" ] }, "ifrs-full_ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfOtherComprehensiveIncomeOfAssociatesAndJointVenturesAccountedForUsingEquityMethodThatWillBeReclassifiedToProfitOrLossNetOfTax", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss": { "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Share of other comprehensive income of associates and joint ventures accounted for using equity method that will be reclassified to profit or loss, net of tax", "terseLabel": "Currency translation differences - equity method" } }, "en": { "role": { "documentation": "Share of the other comprehensive income of associates and joint ventures accounted for using the equity method that will be reclassified to profit or loss, net of tax." } } }, "auth_ref": [ "r274" ] }, "iva_ShareOfProfitLossAndDilutionGainLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ShareOfProfitLossAndDilutionGainLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "documentation": "The entity's share of the profit (loss) and dilution gain (loss) of associates accounted for using the equity method.", "label": "Share Of Profit (Loss) and Dilution Gain (Loss) Of Associates Accounted For Using Equity Method", "terseLabel": "Share of net loss (Equity method) and dilution gain" } } }, "auth_ref": [] }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Share of profit (loss) of associates accounted for using equity method", "totalLabel": "Share of net profit (loss) - Equity method" } } }, "auth_ref": [ "r356" ] }, "iva_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethodBeforeEliminations", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails": { "parentTag": "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails" ], "lang": { "en-us": { "role": { "documentation": "Share of profit (loss) of associates accounted for using equity method before eliminations", "label": "Share of profit (loss) of associates accounted for using equity method before eliminations", "terseLabel": "Share of net loss" } } }, "auth_ref": [] }, "ifrs-full_ShareOptionsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShareOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Share options [member]", "terseLabel": "Stock options" } }, "en": { "role": { "documentation": "This member stands for share options." } } }, "auth_ref": [ "r335" ] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r317", "r323" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Premiums related to share capital" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r244" ] }, "iva_ShortTermDepositAccountsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ShortTermDepositAccountsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for short-term deposit accounts.", "label": "Shortterm deposit accounts", "terseLabel": "Short-term deposit accounts" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionDebtDerivativesAndRoyaltyCertificatesLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Short-term borrowings [member]", "terseLabel": "Short-term debt", "verboseLabel": "Short-term" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r291", "r294" ] }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails": { "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCashAndCashEquivalentsBalanceFromStatementOfCashFlowsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "verboseLabel": "Other cash equivalents" } }, "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r340" ] }, "ifrs-full_ShorttermDepositsNotClassifiedAsCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "ShorttermDepositsNotClassifiedAsCashEquivalents", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails": { "parentTag": "ifrs-full_OtherCurrentAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTaxReceivablesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term deposits, not classified as cash equivalents", "terseLabel": "Short-term deposits", "verboseLabel": "Short-term deposit accounts" } }, "en": { "role": { "documentation": "The amount of short-term deposits held by the entity that are not classified as cash equivalents. [Refer: Cash equivalents]" } } }, "auth_ref": [ "r352" ] }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Associates [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r23", "r78", "r226" ] }, "ifrs-full_SignificantInvestmentsInAssociatesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInAssociatesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossShareOfNetProfitEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionInvestmentsAccountedForUsingEquityMethodDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfIncomeLossInvestmentInHepalysIsAccountedForUsingEquityMethodDetails" ], "lang": { "en-us": { "role": { "label": "Associates [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "auth_ref": [ "r21", "r23", "r78", "r226" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r21", "r23", "r77", "r225" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureBasisOfPreparationAndStatementOfComplianceSignificantInvestmentsInSubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r21", "r23", "r77", "r225" ] }, "ifrs-full_SignificantUnobservableInputLiabilities": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SignificantUnobservableInputLiabilities", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input, liabilities", "terseLabel": "Significant unobservable input, liabilities" } }, "en": { "role": { "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities." } } }, "auth_ref": [ "r81" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Social security contributions", "negatedLabel": "Payroll taxes" } } }, "auth_ref": [ "r334" ] }, "iva_SocieteGeneraleMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SocieteGeneraleMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Societe Generale.", "label": "Societe Generale" } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Consolidated statement of changes in shareholders' equity" } }, "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquity", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r244" ] }, "iva_StatementOfComplianceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StatementOfComplianceAbstract", "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Basis of preparation and statement of compliance" } } }, "auth_ref": [] }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "StatementScenarioAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockIssuedDuringPeriodShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period.", "label": "Stock Issued During Period, Shares", "terseLabel": "Number of shares issued during the period" } } }, "auth_ref": [] }, "iva_StockIssuedDuringPeriodSharesWarrantExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockIssuedDuringPeriodSharesWarrantExercised", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during period upon exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrant Exercised", "terseLabel": "Shares issued during period upon exercise of warrants" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20241Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20241Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2024-1'.", "label": "Stock Options Plan 2024-1 [Member]", "terseLabel": "SO 2024-1" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20242Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20242Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2024-2'.", "label": "Stock Options Plan 2024-2 [Member]", "terseLabel": "SO 2024-2" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20251Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20251Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-1'.", "label": "Stock Options Plan 2025-1 [Member]", "terseLabel": "SO 2025-1" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20252Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20252Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-2'.", "label": "Stock Options Plan 2025-2 [Member]", "terseLabel": "SO 2025-2" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20253Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20253Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2025-3'.", "label": "Stock Options Plan 2025-3 [Member]", "terseLabel": "SO 2025-3" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20261Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20261Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2026-1'.", "label": "Stock Options Plan 2026-1 [Member]", "terseLabel": "SO 2026-1" } } }, "auth_ref": [] }, "iva_StockOptionsPlan20262Member": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "StockOptionsPlan20262Member", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for the stock option plan 'SO 2026-2'.", "label": "Stock Options Plan 2026-2 [Member]", "terseLabel": "SO 2026-2" } } }, "auth_ref": [] }, "iva_Studies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "Studies", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Expense from studies", "label": "Studies", "negatedLabel": "Studies" } } }, "auth_ref": [] }, "iva_SubsidiesIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SubsidiesIncome", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails": { "parentTag": "iva_OtherIncomeFromOrdinaryActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossRevenuesAndOtherIncomeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of income from subsidies.", "label": "Subsidies income", "terseLabel": "Subsidies" } } }, "auth_ref": [] }, "iva_SupplierFisherClinicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SupplierFisherClinicalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for supplier Fisher Clinical.", "label": "Supplier Fisher Clinical [Member]", "terseLabel": "Supplier Fisher Clinical" } } }, "auth_ref": [] }, "iva_SupplierMarkenSasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SupplierMarkenSasMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationCommitmentsGivenAndReceivedDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for supplier Marken SAS.", "label": "Supplier Marken SAS [Member]", "terseLabel": "Supplier Marken SAS" } } }, "auth_ref": [] }, "iva_SupportCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SupportCosts", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails": { "parentTag": "iva_OperatingExpenseExcludingOtherOperatingIncomeExpense", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossOperatingExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Support costs expense.", "label": "Support costs", "negatedLabel": "Support costs (including taxes)" } } }, "auth_ref": [] }, "iva_SusanColesChiefLegalOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "SusanColesChiefLegalOfficerMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for Susan Coles, Chief Legal Officer.", "label": "Susan Coles, Chief Legal Officer [Member]", "terseLabel": "Susan Coles, Chief Legal Officer" } } }, "auth_ref": [] }, "iva_T1BisBsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T1BisBsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T1 bis BSA warrants.", "label": "T1 bis BSA Warrants [Member]", "terseLabel": "T1 bis BSA Warrants" } } }, "auth_ref": [] }, "iva_T1BsaPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T1BsaPrefundedWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T1 BSA pre-funded warrants.", "label": "T1 BSA Prefunded Warrants [Member]", "terseLabel": "T1 BSA Prefunded Warrants" } } }, "auth_ref": [] }, "iva_T2BsaPrefundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T2BsaPrefundedWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 BSA pre-funded warrants.", "label": "T2 BSA Prefunded Warrants [Member]", "terseLabel": "T2 BSA Prefunded Warrants" } } }, "auth_ref": [] }, "iva_T2NewShareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T2NewShareMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfChangesInShareholdersEquityParenthetical" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 New Share.", "label": "T2 New Share [Member]", "terseLabel": "T2 New Share" } } }, "auth_ref": [] }, "iva_T2NewSharesAndT2BsasCallOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T2NewSharesAndT2BsasCallOptionsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShortTermDerivativeDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T2 New Shares and T2 BSAs call options.", "label": "T2 New Shares and T2 BSAs Call Options [Member]", "terseLabel": "T2 New Shares and T2 BSAs call options", "verboseLabel": "T2 New Shares and T2 BSAs" } } }, "auth_ref": [] }, "iva_T3BsaWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T3BsaWarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T3 BSA warrants.", "label": "T3 BSA Warrants [Member]", "verboseLabel": "T3 BSA warrants" } } }, "auth_ref": [] }, "iva_T3WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "T3WarrantsMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for T3 warrants.", "label": "T3 Warrants [Member]", "terseLabel": "T3 Warrants" } } }, "auth_ref": [] }, "iva_ThresholdNumberOfPriorBusinessDaysForObtainingFdaApproval": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "ThresholdNumberOfPriorBusinessDaysForObtainingFdaApproval", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of prior business days within which the company must obtain FDA approval.", "label": "Threshold Number Of Prior Business Days For Obtaining FDA Approval", "terseLabel": "Business days" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2025", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ifrs-full_TopOfRangeMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TopOfRangeMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureAccountingPrinciplesGoingConcernDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLeaseLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Maximum" } }, "en": { "role": { "documentation": "This member stands for top of a range." } } }, "auth_ref": [ "r53", "r83", "r94", "r103", "r166", "r297", "r299", "r344" ] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Trade payable" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r251" ] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 }, "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesDetails": { "parentTag": "iva_TradePayablesAndOtherCurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r321", "r355" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Trade receivables and others" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r234", "r249", "r262" ] }, "iva_TradePayableAndOtherCurrentLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradePayableAndOtherCurrentLiabilitiesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Line Items]", "terseLabel": "Other current and non-current liabilities", "verboseLabel": "Trade payables and short-term contract liabilities" } } }, "auth_ref": [] }, "iva_TradePayableAndOtherCurrentLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradePayableAndOtherCurrentLiabilitiesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionAdditionalInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesBreakDownDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Trade Payable And Other Current Liabilities [Table]" } } }, "auth_ref": [] }, "iva_TradePayablesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradePayablesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradePayablesDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of trade payables and other current liabilities.", "label": "Trade Payables And Other Current Liabilities.", "totalLabel": "Trade payables and other current liabilities" } } }, "auth_ref": [] }, "iva_TradePayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradePayablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member stands for trade payables.", "label": "Trade payables [Member]", "terseLabel": "Trade payables" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesLineItems", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.", "label": "Trade Receivables and Other Current Assets and Receivables [Line Items]", "terseLabel": "Trade receivables, tax receivables and other current assets" } } }, "auth_ref": [] }, "iva_TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "TradeReceivablesAndOtherCurrentAssetsAndReceivablesTable", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTradeReceivablesDetails" ], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to trade receivables and other current assets and receivables.", "label": "Trade Receivables and Other Current Assets and Receivables [Table]" } } }, "auth_ref": [] }, "ifrs-full_TradeReceivablesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TradeReceivablesMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionFinancialAssetsAndLiabilitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Trade receivables" } }, "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r114", "r118", "r219", "r222", "r303", "r349" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r104", "r209" ] }, "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "TypesOfSharebasedPaymentArrangementsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionTables" ], "lang": { "en-us": { "role": { "label": "Types of share-based payment arrangements [domain]" } }, "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } } }, "auth_ref": [ "r104", "r209" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2025", "localname": "USD", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionOtherDetails" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "iva_UncommittedDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "UncommittedDebtFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureOtherFinancialInformationFinancialRiskManagementDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents Uncommitted debt from the 2026 Debt Financing Transaction with BlackRock and Claret Capital.", "label": "Uncommitted debt from 2026 Debt Financing Transaction with BlackRock and Claret Capital [member]", "terseLabel": "Additional Lenders' Tranche" } } }, "auth_ref": [] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnderlyingEquityInstrumentAndDepositaryReceiptsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionShareholdersEquityChangesInShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Underlying equity instrument and depositary receipts [domain]" } }, "en": { "role": { "documentation": "This member stands for the standard value for the \u2018Underlying equity instrument and depositary receipts\u2019 axis if no other member is used." } } }, "auth_ref": [ "r349" ] }, "ifrs-full_UnobservableInputsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsAxis", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r81", "r342" ] }, "ifrs-full_UnobservableInputsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "UnobservableInputsDomain", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionRoyaltyCertificatesLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Unobservable inputs [domain]" } }, "en": { "role": { "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used." } } }, "auth_ref": [ "r81", "r342" ] }, "iva_VolumeWeightedAveragePricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "VolumeWeightedAveragePricePerShare", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Volume-weighted average trading price per ordinary share of the entity over the applicable 30-day period.", "label": "Volume Weighted Average Price Per Share", "terseLabel": "Trading price" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "calculation": { "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails": { "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossPersonnelCostsAndHeadcountDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages, salaries and similar costs" } } }, "auth_ref": [ "r334" ] }, "iva_WarrantExercisePricePremiumPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantExercisePricePremiumPercentage", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of premium applied in determining the exercise price of warrants over the applicable reference share price.", "label": "Warrant Exercise Price Premium Percentage", "terseLabel": "Percentage of premium exercise price" } } }, "auth_ref": [] }, "iva_WarrantRepurchaseOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantRepurchaseOptionMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents warrant repurchase options.", "label": "Warrant repurchase option [Member]", "terseLabel": "Warrant repurchase options" } } }, "auth_ref": [] }, "iva_WarrantsCallOptionStrikePrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsCallOptionStrikePrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Strike price of a warrant that gives the holder the rights, but not the obligation, to purchase or sell an underlying asset.", "label": "Warrants, Call Option, Strike Price", "terseLabel": "Strike price" } } }, "auth_ref": [] }, "iva_WarrantsCapOfPutOption": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsCapOfPutOption", "crdr": "debit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Cap of the put option used to calculate fair value of warrants.", "label": "Warrants, Cap of Put Option", "terseLabel": "Cap of the put option (k\u20ac)" } } }, "auth_ref": [] }, "iva_WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossFinancialIncomeAndExpensesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionChangesInLiabilitiesArisingFromFinancingActivitiesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents warrants from the 2026 Debt Financing Transaction with BlackRock and Claret Capital.", "label": "Warrants from 2026 Debt Financing Transaction with BlackRock and Claret Capital [member]", "terseLabel": "Lenders' warrants" } } }, "auth_ref": [] }, "iva_WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheAndBMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheAndBMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents warrants from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A and B.", "label": "Warrants from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche A and B [member]", "terseLabel": "Lenders' warrants, Tranche A and B" } } }, "auth_ref": [] }, "iva_WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsFrom2026DebtFinancingTransactionWithBlackrockAndClaretCapitalTrancheCMember", "presentation": [ "http://www.inventivapharma.com/role/DisclosureCompanyInformationCombinedTransactionDetails", "http://www.inventivapharma.com/role/DisclosureCompanyInformationDebtFinancingTransactionsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionCreditFacilityAgreementWithEuropeanInvestmentBankDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "This member represents warrants from the 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche C.", "label": "Warrants from 2026 Debt Financing Transaction with BlackRock and Claret Capital, Tranche C [member]", "terseLabel": "Lenders' warrants, Tranche C" } } }, "auth_ref": [] }, "iva_WarrantsMaturity": { "xbrltype": "durationItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsMaturity", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Maturity term used to calculate fair value of warrants.", "label": "Warrants, maturity", "terseLabel": "Maturity (years)" } } }, "auth_ref": [] }, "iva_WarrantsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsRiskFreeInterestRate", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Risk free interest rate used to calculate fair value of warrants.", "label": "Warrants, Risk Free Interest Rate", "verboseLabel": "Risk free rate" } } }, "auth_ref": [] }, "iva_WarrantsStockPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsStockPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Stock price used to calculate fair value of warrants.", "label": "Warrants, Stock Price", "terseLabel": "Stock price" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsSubscriptionPrice", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price per warrant.", "label": "Warrants, Subscription Price", "verboseLabel": "Subscription price per warrant" } } }, "auth_ref": [] }, "iva_WarrantsSubscriptionPriceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsSubscriptionPriceAmount", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The subscription price payable for the warrants to be issued pursuant to the forward contract.", "label": "Warrants, Subscription Price, Amount", "terseLabel": "Subscription price" } } }, "auth_ref": [] }, "iva_WarrantsThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsThresholdTradingDays", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified trading days that common stock price to conversion price of warrants must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.", "label": "Warrants, Threshold Trading Days", "terseLabel": "Threshold trading days of warrants" } } }, "auth_ref": [] }, "iva_WarrantsUnitFairValue": { "xbrltype": "decimalItemType", "nsuri": "http://www.inventivapharma.com/20260630", "localname": "WarrantsUnitFairValue", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionForwardContractRelatingToNewEibWarrantsDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails" ], "lang": { "en-us": { "role": { "documentation": "The fair value per unit of warrants outstanding.", "label": "Warrants, Unit Fair Value", "verboseLabel": "Unit Fair value (\u20ac)" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement", "verboseLabel": "Exercise price" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionLongTermDerivativesDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInBspceAndBsaShareWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Exercise price (in euros)" } }, "en": { "role": { "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r343" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, other equity instruments granted", "verboseLabel": "Fair value per instrument at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r107" ] }, "ifrs-full_WeightedAverageFairValueAtMeasurementDateShareOptionsGranted": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageFairValueAtMeasurementDateShareOptionsGranted", "crdr": "credit", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average fair value at measurement date, share options granted", "terseLabel": "Fair value per SO at grant date" } }, "en": { "role": { "documentation": "The weighted average fair value of share options granted during the period at the measurement date. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r106" ] }, "ifrs-full_WeightedAverageSharePrice2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageSharePrice2019", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionMovementsInAgaDetails", "http://www.inventivapharma.com/role/DisclosureNotesToUnauditedInterimCondensedConsolidatedStatementOfFinancialPositionStockOptionsSoDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Share price" } }, "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r102" ] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2025-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://www.inventivapharma.com/role/DisclosureNotesToInterimCondensedConsolidatedStatementOfIncomeLossBasicAndDilutedLossPerShareDetails", "http://www.inventivapharma.com/role/StatementInterimCondensedConsolidatedStatementOfIncomeLoss" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of shares outstanding used to calculate basic loss per share" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r26" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2025-en-r&anchor=para_21&doctype=Standard", "URIDate": "2025-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_79&doctype=Standard", "URIDate": "2025-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2025-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2025-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2025-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73&doctype=Standard", "URIDate": "2025-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2025-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2025-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2025-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_142&doctype=Standard", "URIDate": "2025-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS19_g2-7_TI", "URIDate": "2025-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2025-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2025-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2025-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2025-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2025-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2025-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2025-en-r&anchor=para_19&doctype=Standard", "URIDate": "2025-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2025-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2025-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2025-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2025-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2025-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2025-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_67&doctype=Standard", "URIDate": "2025-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2025-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2025-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2025-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2025-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2025-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2025-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_b&doctype=Standard", "URIDate": "2025-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2025-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_84&doctype=Standard", "URIDate": "2025-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2025-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2025-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_118&doctype=Standard", "URIDate": "2025-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2025-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2025-en-r&anchor=para_126&doctype=Standard", "URIDate": "2025-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_76&doctype=Standard", "URIDate": "2025-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2025-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2025-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2025-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_50&doctype=Standard", "URIDate": "2025-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2025-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2025-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_10&doctype=Standard", "URIDate": "2025-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14&doctype=Standard", "URIDate": "2025-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_28&doctype=Standard", "URIDate": "2025-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B_d&doctype=Standard", "URIDate": "2025-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2025-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2025-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "10", "IssueDate": "2025-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2025-en-r&anchor=para_22&doctype=Standard", "URIDate": "2025-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2025-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2025-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "2", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_2_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "21", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ix", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B14", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B14_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2025-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2025-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2025-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "14", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2025-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2025-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_105&doctype=Standard", "URIDate": "2025-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2025-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_114&doctype=Standard", "URIDate": "2025-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2025-en-r&anchor=para_97&doctype=Standard", "URIDate": "2025-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109&doctype=Standard", "URIDate": "2025-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2025-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_120&doctype=Standard", "URIDate": "2025-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2025-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2025-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2025-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2025-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2025-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2025-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2025-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "51", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_51_a&doctype=Standard", "URIDate": "2025-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2025-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2025-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2025-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2025-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_25&doctype=Standard", "URIDate": "2025-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2025-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2025-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2025-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2025-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_36&doctype=Standard", "URIDate": "2025-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2025-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2025-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2025-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_e&doctype=Standard", "URIDate": "2025-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_f&doctype=Standard", "URIDate": "2025-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2025-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "8", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_8&doctype=Standard", "URIDate": "2025-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B2", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2025-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2025-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2025-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard", "URIDate": "2025-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2025-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2025-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2025-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2025-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2025-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_32&doctype=Standard", "URIDate": "2025-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2025-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard", "URIDate": "2025-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2025-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_34&doctype=Standard", "URIDate": "2025-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2025-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2025-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20B&doctype=Standard", "URIDate": "2025-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2026-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "30A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_30A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "108", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_108_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2025-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_a&doctype=Standard", "URIDate": "2025-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124_c&doctype=Standard", "URIDate": "2025-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_124&doctype=Standard", "URIDate": "2025-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "133", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_133_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "160", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_160_a&doctype=Standard", "URIDate": "2025-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_a&doctype=Standard", "URIDate": "2025-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_c&doctype=Standard", "URIDate": "2025-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166_d&doctype=Standard", "URIDate": "2025-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "166", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_166&doctype=Standard", "URIDate": "2025-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "168", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_168_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "169", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_169&doctype=Standard", "URIDate": "2025-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "176", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_176&doctype=Standard", "URIDate": "2025-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "190", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_190&doctype=Standard", "URIDate": "2025-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "192", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_192&doctype=Standard", "URIDate": "2025-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_i&doctype=Standard", "URIDate": "2025-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_c_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_i&doctype=Standard", "URIDate": "2025-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "194", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_194_f&doctype=Standard", "URIDate": "2025-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_d&doctype=Standard", "URIDate": "2025-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200_e&doctype=Standard", "URIDate": "2025-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "200", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_200&doctype=Standard", "URIDate": "2025-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "206", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_206_a&doctype=Standard", "URIDate": "2025-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "207", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_207_c&doctype=Standard", "URIDate": "2025-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_a&doctype=Standard", "URIDate": "2025-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "218", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_218_b&doctype=Standard", "URIDate": "2025-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "231", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_231&doctype=Standard", "URIDate": "2025-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2025-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2025-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_a&doctype=Standard", "URIDate": "2025-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "254", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_254_e_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "255", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_255_a&doctype=Standard", "URIDate": "2025-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_a&doctype=Standard", "URIDate": "2025-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_b&doctype=Standard", "URIDate": "2025-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257_c&doctype=Standard", "URIDate": "2025-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "257", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_257&doctype=Standard", "URIDate": "2025-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_c&doctype=Standard", "URIDate": "2025-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263_e&doctype=Standard", "URIDate": "2025-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "263", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_263&doctype=Standard", "URIDate": "2025-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "266", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_266&doctype=Standard", "URIDate": "2025-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "269", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_269&doctype=Standard", "URIDate": "2025-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_c&doctype=Standard", "URIDate": "2025-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "271", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_271_d&doctype=Standard", "URIDate": "2025-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "273", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_273&doctype=Standard", "URIDate": "2025-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "274", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_274_e&doctype=Standard", "URIDate": "2025-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_i&doctype=Standard", "URIDate": "2025-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "28", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_28_a_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b_vi&doctype=Standard", "URIDate": "2025-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31_b&doctype=Standard", "URIDate": "2025-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_31&doctype=Standard", "URIDate": "2025-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "34", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_34_a&doctype=Standard", "URIDate": "2025-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_37&doctype=Standard", "URIDate": "2025-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "43", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_43&doctype=Standard", "URIDate": "2025-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_b&doctype=Standard", "URIDate": "2025-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_c&doctype=Standard", "URIDate": "2025-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44_d&doctype=Standard", "URIDate": "2025-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_44&doctype=Standard", "URIDate": "2025-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "56A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_56A&doctype=Standard", "URIDate": "2025-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "64A", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_64A_b_i&doctype=Standard", "URIDate": "2025-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71_b_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "71", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_71&doctype=Standard", "URIDate": "2025-03-27" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "72", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_72_a&doctype=Standard", "URIDate": "2025-03-27" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2025-03-27" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "75", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_75_c&doctype=Standard", "URIDate": "2025-03-27" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "89", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_89&doctype=Standard", "URIDate": "2025-03-27" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_a&doctype=Standard", "URIDate": "2025-03-27" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "95", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_95_b&doctype=Standard", "URIDate": "2025-03-27" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iii&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a_iv&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B10_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B13", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B13&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2026-01-01", "Name": "IFRS", "Number": "9", "IssueDate": "2025-01-01", "Paragraph": "7.2.49", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2025-en-r&anchor=para_7.2.49&doctype=Standard", "URIDate": "2025-03-27" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_a&doctype=Standard", "URIDate": "2025-03-27" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_i&doctype=Standard", "URIDate": "2025-03-27" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2025-03-27" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106&doctype=Standard", "URIDate": "2025-03-27" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_35&doctype=Standard", "URIDate": "2025-03-27" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_c&doctype=Standard", "URIDate": "2025-03-27" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_e&doctype=Standard", "URIDate": "2025-03-27" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_h&doctype=Standard", "URIDate": "2025-03-27" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_i&doctype=Standard", "URIDate": "2025-03-27" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_k&doctype=Standard", "URIDate": "2025-03-27" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_n&doctype=Standard", "URIDate": "2025-03-27" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_o&doctype=Standard", "URIDate": "2025-03-27" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_q&doctype=Standard", "URIDate": "2025-03-27" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_56&doctype=Standard", "URIDate": "2025-03-27" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61_a&doctype=Standard", "URIDate": "2025-03-27" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_61&doctype=Standard", "URIDate": "2025-03-27" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_66&doctype=Standard", "URIDate": "2025-03-27" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_69&doctype=Standard", "URIDate": "2025-03-27" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_d&doctype=Standard", "URIDate": "2025-03-27" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2025-03-27" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2025-03-27" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_79_a&doctype=Standard", "URIDate": "2025-03-27" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_a&doctype=Standard", "URIDate": "2025-03-27" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_b&doctype=Standard", "URIDate": "2025-03-27" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_81A_c&doctype=Standard", "URIDate": "2025-03-27" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_a&doctype=Standard", "URIDate": "2025-03-27" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_b&doctype=Standard", "URIDate": "2025-03-27" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82_d&doctype=Standard", "URIDate": "2025-03-27" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_91_a&doctype=Standard", "URIDate": "2025-03-27" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_b&doctype=Standard", "URIDate": "2025-03-27" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "98", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_98_d&doctype=Standard", "URIDate": "2025-03-27" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_99&doctype=Standard", "URIDate": "2025-03-27" }, "r279": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2025-03-27" }, "r280": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2025-03-27" }, "r281": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2025-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2025-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r282": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r283": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Paragraph": "87", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&anchor=para_87&doctype=Standard", "URIDate": "2025-03-27" }, "r284": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "37", "IssueDate": "2025-01-01", "Section": "Example 10 A court case", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex10_TI", "URIDate": "2025-03-27" }, "r285": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2025-03-27" }, "r286": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2025-03-27" }, "r287": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2025-03-27" }, "r288": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_d&doctype=Standard", "URIDate": "2025-03-27" }, "r289": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2025-03-27" }, "r290": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44B&doctype=Standard", "URIDate": "2025-03-27" }, "r291": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2025-03-27" }, "r292": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2025-03-27" }, "r293": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2025-03-27" }, "r294": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2025-03-27" }, "r295": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2025-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r296": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_94&doctype=Standard", "URIDate": "2025-03-27" }, "r297": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r298": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r299": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2025-03-27" }, "r300": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2025-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2025-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r301": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2025-03-27" }, "r302": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2025-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2025-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2025-03-27" }, "r303": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2025-03-27" }, "r304": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_6&doctype=Standard", "URIDate": "2025-03-27" }, "r305": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r306": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r307": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_a&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r308": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_e&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r309": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r310": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r311": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r312": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG20D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG20D&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r313": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r314": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r315": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "103", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_103_b&doctype=Standard", "URIDate": "2025-03-27" }, "r316": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_b&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r317": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Effective 2027-01-01", "Name": "IFRS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "B9", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=19&code=ifrs-tx-2025-en-r&anchor=para_B9_f&doctype=Appendix&subtype=B", "URIDate": "2025-03-27" }, "r318": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_102&doctype=Standard", "URIDate": "2025-03-27" }, "r319": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_103&doctype=Standard", "URIDate": "2025-03-27" }, "r320": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r321": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_70&doctype=Standard", "URIDate": "2025-03-27" }, "r322": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r323": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r324": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_82A&doctype=Standard", "URIDate": "2025-03-27" }, "r325": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2025-03-27" }, "r326": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d-3" }, "r328": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2025-01-01", "Paragraph": "80", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2025-en-r&anchor=para_80&doctype=Standard", "URIDate": "2025-03-27" }, "r329": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2025-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2025-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2025-03-27" }, "r330": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2025-03-27" }, "r331": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_141&doctype=Standard", "URIDate": "2025-03-27" }, "r332": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "5", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_5&doctype=Standard", "URIDate": "2025-03-27" }, "r333": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2025-03-27" }, "r334": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2025-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2025-en-r&anchor=para_9&doctype=Standard", "URIDate": "2025-03-27" }, "r335": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2025-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2025-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2025-03-27" }, "r336": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_16&doctype=Standard", "URIDate": "2025-03-27" }, "r337": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_17&doctype=Standard", "URIDate": "2025-03-27" }, "r338": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2025-03-27" }, "r339": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_20&doctype=Standard", "URIDate": "2025-03-27" }, "r340": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r341": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2025-03-27" }, "r342": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "13", "IssueDate": "2025-01-01", "Paragraph": "93", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2025-en-r&anchor=para_93_h&doctype=Standard", "URIDate": "2025-03-27" }, "r343": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "2", "IssueDate": "2025-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2025-en-r&anchor=para_45&doctype=Standard", "URIDate": "2025-03-27" }, "r344": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "7", "IssueDate": "2025-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2025-en-r&anchor=para_7&doctype=Standard", "URIDate": "2025-03-27" }, "r345": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_10_e&doctype=Standard", "URIDate": "2025-03-27" }, "r346": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_104&doctype=Standard", "URIDate": "2025-03-27" }, "r347": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_106_d&doctype=Standard", "URIDate": "2025-03-27" }, "r348": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_108&doctype=Standard", "URIDate": "2025-03-27" }, "r349": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_112_c&doctype=Standard", "URIDate": "2025-03-27" }, "r350": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_117&doctype=Standard", "URIDate": "2025-03-27" }, "r351": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_54_a&doctype=Standard", "URIDate": "2025-03-27" }, "r352": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_55&doctype=Standard", "URIDate": "2025-03-27" }, "r353": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_b&doctype=Standard", "URIDate": "2025-03-27" }, "r354": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78_e&doctype=Standard", "URIDate": "2025-03-27" }, "r355": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_78&doctype=Standard", "URIDate": "2025-03-27" }, "r356": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Note": "Expiry date 2027-01-01", "Name": "IAS", "Number": "1", "IssueDate": "2025-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2025-en-b&anchor=para_85&doctype=Standard", "URIDate": "2025-03-27" } } }